

STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 124744

TO: David Lukton
Location: REM-3B75/3C70
Art Unit: 1653
June 18, 2004

Case Serial Number: 10037358

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

SEARCH REQUEST FORM
(STIC)

Access DB# _____

Requestor's Name: David Lukton Examiner number: 71263 Date:

Art Unit: 1653 Phone number: 571-272-0952 Serial Number: 10/037358

Mail Box: 3-C-70 Examiner Rm: 3-B-75 Results format: paper

* * * *

Title: DMT-TIC DI-AND TRI-PEPTIDIC DERIVATIVES AND RELATED
COMPOSITIONS AND METHODS OF USE

Applicants: LAZARUS, LAWRENCE H.; SALVADORI, SEVERO

Earliest Priority Date: 3/24/00

* * * *

Applicants are claiming the following compounds, wherein R' is any of the
substituents listed on the attached sheet

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 16:40:35 ON 18 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2004 VOL 140 ISS 26
 FILE LAST UPDATED: 17 Jun 2004 (20040617/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>


=> d stat que 18
 L1 STR




NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
 L5 326 SEA FILE=REGISTRY SSS FUL L1
 L6 STR



Page 1-A



Page 2-A

VAR G1=HY/27

VAR G2=31/49/61/71

REP G3=(0-1) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 72

STEREO ATTRIBUTES: NONE

L7 34 SEA FILE=REGISTRY SUB=L5 SSS FUL L6

L8 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

=>

=>

=> d ibib abs hitrn 18 1-7

L8 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:923401 HCAPLUS

DOCUMENT NUMBER: 140:263738

TITLE: Synthesis and opioid activity of N,N-Dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent δ

antagonism

AUTHOR(S): Balboni, Gianfranco; Salvadori, Severo; Guerrini, Remo; Negri, Lucia; Giannini, Elisa; Bryant, Sharon D.; Jinsmaa, Yunden; Lazarus, Lawrence H.

CORPORATE SOURCE: Department of Toxicology, University of Cagliari, Cagliari, I-09126, Italy

SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(24), 5435-5441

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB N,N-Dimethylation of the H-Dmt-Tic-NH-CH(R)-R' series of compds. produced no significant effect on the high δ -opioid receptor affinity ($K_i=0.035-0.454$ nM), but dramatically decreased that for the μ -opioid receptor. The effect of N-methylation was independent of the length of the linker (R); however, the bioactivities were affected by the chemical composition of the third aromatic group (R'): Ph (Ph) (5'-8') elicited a greater reduction in μ -affinity (40-70-fold) compared to analogs containing 1H-benzimidazole-2-yl (Bid) (9-fold). The major consequences of N,N-dimethylation on in vitro bioactivity were: (i) a loss of δ -agonism coupled with the appearance of potent δ antagonism; and (ii) a consistent loss of μ -affinity resulted in enhanced δ -opioid receptor selectivity. With the exception of one compound, the change in the hydrophobic environment at the N-terminus and formation of a tertiary amine by N,N-dimethylation in analogs of the Dmt-Tic pharmacophore produced potent δ -selective antagonists.

IT 403652-09-5P 403652-10-8P 403652-11-9P 403652-12-0P 403652-13-1P 403652-14-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and opioid activity of Dmt-Tic analogs)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:892613 HCAPLUS

DOCUMENT NUMBER: 139:381482

TITLE: Preparation of 4-phenylimidazoles and related compounds as opioid receptor modulators for the treatment of pain and gastrointestinal disorders

INVENTOR(S): Breslin, Henry J.; He, Wei; Kavash, Robert W.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092688	A2	20031113	WO 2003-US11872	20030417
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,			

NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

US 2004010014 A1 20040115 US 2003-400006 20030326
PRIORITY APPLN. INFO.: US 2002-376406P P 20020429
US 2003-400006 A 20030326
OTHER SOURCE(S): MARPAT 139:381482
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, N(R14), etc.; R14 = H, alkyl, aryl, etc.; R1 = (un)substituted benzimidazole, benzoxazole, benzothiazole, etc.; R2 = (un)substituted CH₂CH₂, e.g., halo, phenylmethyl; R3, R4 = H, alkyl aryl, etc.; R5, R6 = H, alkyl, aryl, etc.; n, r = 0-2; L = O, S, H₂, etc.; R8, R9 = H or alkyl with provisos; s = 0-3; R9 = H, alkyl; R10, R11 = H, alkyl; p = 0-3; R12, R13 = H, alkyl, formyl, etc.; Ar = Ph, naphthyl, heteroaryl; Z = 0-4 substituents consisting of halo, alkyl, alkoxy, etc.] and their pharmaceutically acceptable salts were prepared For example, reductive amination of acetone with amine II, e.g., prepared from (3S)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-tert-Bu ester in 4-steps, followed by phenol deprotection afforded claimed phenylimidazole III. In rat brain δ -opioid receptor binding assays, approx. 90-examples of compds. I exhibited K_i values ranging from 0.06-50,000 nM, e.g., the K_i value of phenylimidazole III was 11.9 nM. Compds. I are claimed useful as opioid receptor modulators, antagonists and agonists for the treatment of pain and gastrointestinal disorders.

IT 623949-66-6P 623949-67-7P 623949-68-8P
623949-83-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of 4-phenylimidazoles and related compds. as opioid receptor modulators for the treatment of pain and gastrointestinal disorders)

L8 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:851286 HCAPLUS

DOCUMENT NUMBER: 138:66167

TITLE: Potent δ -Opioid Receptor Agonists Containing the Dmt-Tic Pharmacophore

AUTHOR(S): Balboni, Gianfranco; Salvadori, Severo; Guerrini, Remo; Negri, Lucia; Giannini, Elisa; Jinsmaa, Yunden; Bryant, Sharon D.; Lazarus, Lawrence H.

CORPORATE SOURCE: Department of Toxicology, University of Cagliari, Cagliari, I-09126, Italy

SOURCE: Journal of Medicinal Chemistry (2002), 45(25), 5556-5563

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:66167

AB Conversion of δ -opioid receptor antagonists containing the 2',6'-dimethyl-L-tyrosine (Dmt)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) pharmacophore into potent δ -agonists required a third heteroarom. nucleus, such as 1H-benzimidazole-2-yl (Bid) and a linker of specified length both located C-terminally to Tic in the general formula H-Dmt-Tic-NH-CH(R)-R'. The distance between Tic and Bid is a determining factor responsible for the acquisition of δ agonism or δ antagonism. Compds. containing a C-terminal Ala, Asp, or Asn with an amide or

free acid group served as δ -antagonist controls lacking the third heteroarom. ring. A change in chirality of the spacer or inclusion of a neg. charge via derivs. of Asp resulted in potent δ agonism and moderate μ agonism, although δ -receptor affinity decreased about 10-fold for one peptide while μ affinity fell by over 2 orders of magnitude. Repositioning of the neg. charge in the linker altered activity: H-Dmt-Tic-NH-CH(CH₂-Bid)COOH maintained high δ affinity (K_i = 0.042 nM) and δ agonism (IC_{50} = 0.015 nM), but attachment of the free acid group to Bid [H-Dmt-Tic-NH-CH₂-Bid(CH₂-COOH)] reconstituted δ antagonism (K_e = 0.27 nM). The data demonstrate that a linker separating the Dmt-Tic pharmacophore and Bid, regardless of the presence of a neg. charge, is important in the acquisition of opioids exhibiting potent δ agonism and weak μ agonism from a parent δ antagonist.

IT 403652-10-8 403652-11-9 480446-47-7

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(preparation and structure-activity relationship of potent δ -opioid receptor agonists containing the Dmt-Tic pharmacophore)

IT 480446-43-3P 480446-44-4P 480446-45-5P

480446-46-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure-activity relationship of potent δ -opioid receptor agonists containing the Dmt-Tic pharmacophore)

IT 480446-49-9P 480446-50-2P 480446-51-3P

480446-54-6P 480446-57-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(preparation and structure-activity relationship of potent δ -opioid receptor agonists containing the Dmt-Tic pharmacophore)

IT 480446-89-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and structure-activity relationship of potent δ -opioid receptor agonists containing the Dmt-Tic pharmacophore)

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:833557 HCAPLUS

DOCUMENT NUMBER: 137:338140

TITLE: Preparation of 2',6'-dimethyltyrosinyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (Dmt-tic) di- and tri-peptidic derivatives as δ -opioid antagonists

INVENTOR(S): Lazarus, Lawrence H.; Salvadori, Severo

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U. S. Ser. No. 814,558.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161189	A1	20021031	US 2001-37358	20011221
WO 2003062261	A2	20030731	WO 2002-US40770	20021220
WO 2003062261	A3	20040212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2000-192128P P 20000324

US 2001-814558 A2 20010322

US 2001-37358 A 20011221

OTHER SOURCE(S): MARPAT 137:338140

AB The invention relates to di- and tripeptidic derivs. comprising the pharmacophore H-Dmt-Tic-X-Y (Tic = 2',6'-dimethyltyrosine, Tic = 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, X is a spacer comprising one or more amino acid residues and Y comprises an aromatic group) and related compns. and methods of use. The Dmt-Tic pharmacophore represents a distinct class of δ -opioid antagonists. Thus, H-Dmt-Tic-NH-tetrazol-5-yl.TFA was prepared by coupling of Boc-protected Dmt with H-Tic-OMe, amidation with 5-aminotetrazole and deprotection. Results of binding of compds. of the invention to α -opioid and μ -opioid receptors are tabulated. The binding data are discussed in terms of variation in structure of the compds.

IT 474013-80-4P 474013-82-6P 474013-84-8P

474013-86-0P 474013-89-3P 474015-40-2P

474015-45-7P 474015-50-4P 474015-53-7P

474015-57-1P 474015-63-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dimethyltyrosinyltetrahydroisoquinolinecarboxylic acid (Dmt-tic) di- and tri-peptidic derivs. as δ -opioid antagonists)

L8 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:692538 HCAPLUS

DOCUMENT NUMBER: 138:338458

TITLE: Synthesis and pharmacological activity of Dmt-Tic analogs with highly potent agonist and antagonist/agonist opioid activity

AUTHOR(S): Guerrini, Remo; Balboni, Gianfranco; Rizzi, Daniela; Calo, Girolamo; Bryant, Sharon D.; Lazarus, Lawrence H.; Salvadori, Severo

CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of Ferrara, Ferrara, 44-100, Italy

SOURCE: Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 679-680. Editor(s): Lebl, Michal; Houghten, Richard A. American Peptide Society: San Diego, Calif.

CODEN: 69DBAL; ISBN: 0-9715560-0-8

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A symposium report. Dmt-Tic analogs (Dmt = 2,6-dimethyl-L-tyrosine residue, Tic = L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid residue) were synthesized and their in vitro opioid activities determined. Introduction of a pharmacophore [N-1H-benzimidazol-2-yl (Bid), N-Ph, or N-benzyl amide] at the C-terminal of Dmt-Tic significantly increased μ receptor affinity and induced agonist activity in the guinea pig ileum. In the mouse vas deferens assay, the compds. were agonists only when the second pharmacophore (Bid or N-Ph amide) was located at a minimal distance from the aromatic nuclei Dmt-Tic. Bid was better than N-Ph amide for activation of the δ -opioid receptor.

IT 403652-10-8P 403652-11-9P 403652-12-0P

403652-13-1P 403652-14-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and pharmacol. activity of Dmt-Tic analogs with highly potent agonist and antagonist/agonist opioid activity)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:14209 HCAPLUS

DOCUMENT NUMBER: 136:226323

TITLE: Evaluation of the Dmt-Tic Pharmacophore: Conversion of a Potent δ -Opioid Receptor Antagonist into a Potent δ Agonist and Ligands with Mixed Properties

AUTHOR(S): Balboni, Gianfranco; Guerrini, Remo; Salvadori, Severo; Bianchi, Clementina; Rizzi, Daniela; Bryant, Sharon D.; Lazarus, Lawrence H.

CORPORATE SOURCE: Department of Toxicology, University of Cagliari, Cagliari, 09126, Italy

SOURCE: Journal of Medicinal Chemistry (2002), 45(3), 713-720
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Analogs of the 2',6'-dimethyl-L-tyrosine (Dmt)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) pharmacophore were prepared to test the hypothesis that a "spacer" and a third aromatic center in opioid peptides are required to convert a δ -antagonist into ligands with δ -agonist or with mixed δ -antagonist/ μ -agonist properties. Potent δ -agonists and bifunctional compds. with high δ - and μ -opioid receptor affinities were obtained by varying the spacer length [none, NH-CH₂, NH-CH₂-CH₂, Gly-NH-CH₂] and C-terminal aromatic nucleus [1H-benzimidazole-2-yl, Ph and benzyl groups]. C-terminal modification primarily affected μ -opioid receptor affinities, which increased maximally 1700-fold relative to the prototype δ -antagonist H-Dmt-Tic-NH₂ and differentially modified bioactivity. In the absence of a spacer (1), the analog exhibited dual δ -agonism (pEC₅₀, 7.28) and δ -antagonism (pA₂, 7.90). H-Dmt-Tic-NH-CH₂-1H-benzimidazol-2-yl (Bid) (2) became a highly potent δ -agonist (pEC₅₀, 9.90), slightly greater than deltorphin C (pEC₅₀, 9.56), with μ -agonism (pE₅₀, 7.57), while H-Dmt-Tic-Gly-NH-CH₂-Bid (4) retained potent δ -antagonism (pA₂, 9.0) but with an order of magnitude less μ -agonism. Similarly, H-Dmt-Tic-Gly-NH-Ph (5) had nearly equivalent high δ -agonism (pEC₅₀, 8.52) and μ -agonism (pEC₅₀, 8.59), while H-Dmt-Tic-Gly-NH-CH₂-Ph (6) whose spacer was longer by a single methylene group exhibited potent δ -antagonism (pA₂, 9.25) and very high μ -agonism (pEC₅₀, 8.57). These data confirm that the distance between the Dmt-Tic pharmacophore and a third aromatic nucleus is an important criterion in converting Dmt-Tic from a highly potent δ -antagonist into a potent δ -agonist or into ligands with mixed δ - and μ -opioid properties.

IT **403652-09-5P 403652-10-8P 403652-11-9P**

403652-12-0P 403652-13-1P 403652-14-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(evaluation of Dmt-Tic pharmacophore: conversion of a potent δ -opioid receptor antagonist into a potent δ agonist and ligands with mixed properties)

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:828316 HCAPLUS

DOCUMENT NUMBER: 134:66089
 TITLE: Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei
 AUTHOR(S): Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H.
 CORPORATE SOURCE: Department of Toxicology, University of Cagliari, Cagliari, I-09126, Italy
 SOURCE: Peptides (New York) (2000), 21(11), 1663-1671
 CODEN: PPTDD5; ISSN: 0196-9781
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB In lieu of H-Dmt-Tic-OH, H-Dmt-analogs included 2-amino-3(1H-benzoimidazol-2-yl)-propionic acid, N(Bzl)Gly, L-octahydroindole-2-carboxylic acid, [3S-(3 α ,4 α ,8 α)]-decahydro-3-isoquinoline carboxylic acid, benzimidazole-, pyridoindole- or spiroinden-derivs., or C-terminally modified. L- Or D-Ala, Sar, or Pro were spacers between aromatic nuclei. Only H-Dmt-(Xaa-)-pyridoindole exhibited high affinities with δ and μ antagonism. The peptides competed equally against [3H]DPDPE (δ agonist) or [3H]N,N(CH₃)₂-Dmt-Tic-OH (δ antagonist) signaling a single δ binding site. The data confirm the importance of Tic for δ affinity and antagonism, while heterocyclic or heteroaliph. nuclei, or spacer exert effects on μ - and δ -receptor properties.

IT 314756-49-5P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (opioid pseudopeptides containing heteroarom. or heteroaliph. nuclei)

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=>

=> fil caold

FILE 'CAOLD' ENTERED AT 16:41:19 ON 18 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=>

=> => s 17

L9 0 L7

=>

=>

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:41:30 ON 18 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUN 2004 HIGHEST RN 694921-36-3
 DICTIONARY FILE UPDATES: 17 JUN 2004 HIGHEST RN 694921-36-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>


=>

=>

=> d ide can 17 tot

L7 ANSWER 1 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 623949-83-7 REGISTRY
 CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-(4-methyl-5-phenyl-1H-imidazol-2-yl)-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H32 N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:381482

L7 ANSWER 2 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 623949-68-8 REGISTRY
CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-3-(4-chloro-5-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H29 Cl N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:381482

L7 ANSWER 3 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 623949-67-7 REGISTRY
CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-3-(4-bromo-5-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H29 Br N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:381482

L7 ANSWER 4 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 623949-66-6 REGISTRY
CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-(4-phenyl-1H-imidazol-2-yl)-, (3S)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C29 H30 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 139:381482

L7 ANSWER 5 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 480446-89-7 REGISTRY
 CN 1H-Benzimidazole-1-acetic acid, 2-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]methyl]-, ethyl ester, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H37 N5 O5 .. 2 C2 H F3 O2
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT
 DT.CA CAPLUS document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

CM 1


CRN 480446-88-6
 CMF C33 H37 N5 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 6 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 480446-88-6 REGISTRY
 CN 1H-Benzimidazole-1-acetic acid, 2-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-

isoquinolinyl]carbonyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H37 N5 O5
 CI COM
 SR CA

Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 7 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 480446-57-9 REGISTRY
 CN 1H-Benzimidazole-1-acetic acid, 2-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H33 N5 O5 . 2 C2 H F3 O2
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation); PRP (Properties)

CM 1

CRN 480446-46-6
 CMF C31 H33 N5 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 8 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 480446-54-6 REGISTRY

CN 1H-Benzimidazole-2-propanoic acid, α-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (αS)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C31 H33 N5 O5 . 2 C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Journal


RL.NP Roles from non-patents: PREP (Preparation); PRP (Properties)

CM 1

CRN 480446-45-5

CMF C31 H33 N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 9 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 480446-51-3 REGISTRY

CN 1H-Benzimidazole-2-propanoic acid, β -[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (β S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C31 H33 N5 O5 . 2 C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA CAplus document type: Journal


RL.NP Roles from non-patents: PREP (Preparation); PRP (Properties)

CM 1

CRN 480446-44-4

CMF C31 H33 N5 O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 10 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 480446-50-2 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[(1R)-1-(1H-benzimidazol-2-yl)ethyl]-1,2,3,4-tetrahydro-, (3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H33 N5 O3 . 2 C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Journal


RL.NP Roles from non-patents: PREP (Preparation); PRP (Properties)

CM 1

CRN 480446-47-7

CMF C30 H33 N5 O3


Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 11 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 480446-49-9 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[(1S)-1-(1H-benzimidazol-2-yl)ethyl]-1,2,3,4-tetrahydro-, (3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H33 N5 O3 . 2 C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Journal


RL.NP Roles from non-patents: PREP (Preparation); PRP (Properties)

CM 1

CRN 480446-43-3

CMF C30 H33 N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 12 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 480446-47-7 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[(1R)-1-(1H-benzimidazol-2-yl)ethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H33 N5 O3

CI COM


SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 13 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 480446-46-6 REGISTRY
CN 1H-Benzimidazole-1-acetic acid, 2-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H33 N5 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)

Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 14 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 480446-45-5 REGISTRY
CN 1H-Benzimidazole-2-propanoic acid, α -[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H33 N5 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 15 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 480446-44-4 REGISTRY
CN 1H-Benzimidazole-2-propanoic acid, β -[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (β S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H33 N5 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 16 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 480446-43-3 REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[(1S)-1-(1H-benzimidazol-2-yl)ethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H33 N5 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:66167

L7 ANSWER 17 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 474015-63-9 REGISTRY
 CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[2-oxo-2-[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C30 H34 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 18 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 474015-57-1 REGISTRY
 CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[2-oxo-2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C29 H32 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 19 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 474015-53-7 REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H34 N6 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 20 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 474015-50-4 REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-

oxopropyl]-N-[2-(1H-benzimidazol-2-yl)ethyl]-1,2,3,4-tetrahydro- (9CI)
(CA INDEX NAME)

FS 3D CONCORD


MF C30 H33 N5 O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 21 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 474015-45-7 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-(1H-benzimidazol-2-ylmethyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C29 H31 N5 O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 22 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 474015-40-2 REGISTRY
 CN Isoquinoline, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-3-(1H-benzimidazol-2-yl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H28 N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 137:338140

L7 ANSWER 23 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 474013-89-3 REGISTRY
 CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[2-oxo-2-[(phenylmethyl)amino]ethyl]-, (3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H34 N4 O4 . C2 H F3 O2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1


CRN 403652-14-2
 CMF C30 H34 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 137:338140

L7 ANSWER 24 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 474013-86-0 REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[2-oxo-2-(phenylamino)ethyl]-, (3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H32 N4 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 403652-13-1
CMF C29 H32 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 25 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 474013-84-8 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)-, bis(trifluoroacetate) (salt) (9CI)
(CA INDEX NAME)

FS STEREOSEARCH

MF C31 H34 N6 O4 . 2 C2 H F3 O2

SR	CA
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CApplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 403652-12-0

CMF C31 H34 N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 26 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 474013-82-6 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[2-(1H-benzimidazol-2-yl)ethyl]-1,2,3,4-tetrahydro-, (3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H33 N5 O3 . 2 C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 403652-11-9

CMF C30 H33 N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140


L7 ANSWER 27 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 474013-80-4 REGISTRY
 CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-(1H-benzimidazol-2-ylmethyl)-1,2,3,4-tetrahydro-, (3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H31 N5 O3 . 2 C2 H F3 O2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 403652-10-8

CMF C29 H31 N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

L7 ANSWER 28 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 403652-14-2 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[(phenylmethyl)amino]ethyl-, (3S)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H34 N4 O4

CI COM


SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Conference; Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:263738

REFERENCE 2: 138:338458

REFERENCE 3: 136:226323

L7 ANSWER 29 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 403652-13-1 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[2-oxo-2-(phenylamino)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C29 H32 N4 O4

CI COM


SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Conference; Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 140:263738

REFERENCE 2: 138:338458

REFERENCE 3: 136:226323

L7 ANSWER 30 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 403652-12-0 REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H34 N6 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Conference; Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 140:263738

REFERENCE 2: 138:338458

REFERENCE 3: 136:226323

L7 ANSWER 31 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 403652-11-9 REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[2-(1H-benzimidazol-2-yl)ethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H33 N5 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Conference; Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:263738
REFERENCE 2: 138:338458
REFERENCE 3: 138:66167
REFERENCE 4: 136:226323

L7 ANSWER 32 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 403652-10-8 REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-(1H-benzimidazol-2-ylmethyl)-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H31 N5 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Conference; Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:263738
REFERENCE 2: 138:338458
REFERENCE 3: 138:66167
REFERENCE 4: 136:226323

L7 ANSWER 33 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 403652-09-5 REGISTRY
 CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-3-(1H-benzimidazol-2-yl)-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H28 N4 O2
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:263738

REFERENCE 2: 136:226323

L7 ANSWER 34 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 314756-49-5 REGISTRY
 CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-3-(1H-benzimidazol-2-yl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H28 N4 O2
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:66089

=> □

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:44:34 ON 18 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2004 VOL 140 ISS 26

FILE LAST UPDATED: 17 Jun 2004 (20040617/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

=>

=> => d stat que 115 nos

L1 STR

L5 326 SEA FILE=REGISTRY SSS FUL L1

L6 STR

L7 34 SEA FILE=REGISTRY SUB=L5 SSS FUL L6

L8 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

L10 292 SEA FILE=REGISTRY ABB=ON PLU=ON L5 NOT L7

L13 53 SEA FILE=HCAPLUS ABB=ON PLU=ON L10

L14 46 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 NOT L8
 L15 34 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND PD<= MARCH 24, 2000

=>
 =>

=> d ibib abs hitrn l15 1-34

L15 ANSWER 1 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:894623 HCAPLUS
 DOCUMENT NUMBER: 135:40848
 TITLE: Opioid dipeptide derivatives with a mixed μ agonist/ δ antagonist, partial μ agonist/ δ antagonist or μ agonist/partial δ agonist profile
 AUTHOR(S): Schiller, Peter W.; Weltrowska, Grazyna; Nguyen, Thi M. -D.; Wilkes, Brian C.; Lemieux, Carole; Chung, Nga N.
 CORPORATE SOURCE: Laboratory of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, QC, H2W 1R7, Can.
 SOURCE: Peptides for the New Millennium, Proceedings of the American Peptide Symposium, 16th, Minneapolis, MN, United States, June 26-July 1, 1999 (2000), Meeting Date 1999, 229-230. Editor(s): Fields, Gregg B.; Tam, James P.; Barany, George. Kluwer Academic Publishers: Dordrecht, Neth.
 CODEN: 69ATHX
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB Opioid compds. with a mixed μ agonist/ δ antagonist profile are expected to be analgesics with low propensity to produce tolerance and dependence. The first fully characterized mixed μ agonist/ δ antagonist was the pseudotetrapeptide H-Dmt-Tic[CH₂NH]Phe-Phe-NH₂; Dmt = 2',6'-dimethyltyrosine which produced a potent analgesic effect, no dependence and less tolerance than morphine. In an effort to develop mixed μ agonist/ δ antagonists of lower mol. weight capable of crossing the blood-brain barrier, dipeptide derivs. of the general formula H-Xxx-Tic-NH-R, where Xxx is tyrosine or a tyrosine analog and R represents an aralkyl or alkyl substituent, were synthesized. The dipeptide derivs. were synthesized in solution using the mixed anhydride method. In vitro opioid agonist or antagonist activities of the resulting compds. were determined in the μ receptor-representative guinea pig ileum assay and in the δ receptor-representative mouse vas deferens assay, and their μ , δ , κ opioid receptor affinities were measured in binding assays based on the displacement of μ -, δ - and κ -selective radioligands from rat or guinea pig brain membrane binding sites.
 IT 173927-99-6P 209786-77-6P 344615-76-5P
 344615-77-6P 344615-78-7P 344615-79-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (opioid dipeptide derivs. with mixed μ agonist/ δ antagonist, partial μ agonist/ δ antagonist or μ agonist/partial δ agonist profile)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:853641 HCAPLUS
 DOCUMENT NUMBER: 134:216792

TITLE: Assessment of substitution in the second pharmacophore of Dmt-Tic analogues
 AUTHOR(S): Santagada, V.; Balboni, G.; Caliendo, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Bryant, S. D.; Lazarus, L. H.
 CORPORATE SOURCE: Medicinal Chemistry and Toxicology, University of Naples, Naples, I-80134, Italy
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(24), 2745-2748
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The Dmt-Tic pharmacophore exhibits potent δ -opioid receptor antagonism. Analogs with substitutions in the second pharmacophore with or without a COOH function were synthesized: several had high δ affinity, but exhibited low to non-selectivity toward μ receptors similar to H-Dmt-Tic-amide and H-Dmt-Tic-ol. Functional bioactivity indicated high δ antagonism (pA₂ 7.4-7.9) and modest μ agonism, pEC₅₀ (6.1-6.3), but with E_{max} values analogous to dermorphin. These Dmt-Tic analogs with mixed δ antagonist/ μ agonist properties would appear to be better candidates as analgesics than pure μ agonists.

IT 329320-06-1 329320-07-2
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(opioid receptor binding activity of dimethyltyrosine isoquinolinecarboxylates)

IT 329319-97-3P 329320-03-8P 329320-04-9P
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (opioid receptor binding activity of dimethyltyrosine isoquinolinecarboxylates)

IT 329319-96-2P 329319-98-4P 329319-99-5P
 329320-00-5P 329320-01-6P 329320-02-7P
 329320-05-0P
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (opioid receptor binding activity of dimethyltyrosine isoquinolinecarboxylates)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:677175 HCAPLUS
 DOCUMENT NUMBER: 134:51294
 TITLE: Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue
 AUTHOR(S): Labarre, M.; Butterworth, J.; St-Onge, S.; Payza, K.; Schmidhammer, H.; Salvadori, S.; Balboni, G.; Guerrini, R.; Bryant, S. D.; Lazarus, L. H.
 CORPORATE SOURCE: Department of Pharmacology, AstraZeneca R&D Montreal, St-Laurent, QC, H4S 1Z9, Can.
 SOURCE: European Journal of Pharmacology (2000), 406(1), R1-R3
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The potent δ -opioid receptor antagonist H-2',6-l-tyrosine(Dmt)-

1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic-OH) exhibited partial inverse agonism ($EC_{50}=6.35$ nM, $E_{max}=-18.87\%$) for [^{35}S]GTP γ S binding and H-Dmt-Tic-NH $_2$ was a neutral antagonist (no effect up to 30 μ M). In contrast N,N(CH $_3$) $_2$ -Dmt-Tic-NH $_2$ was a full inverse agonist ($EC_{50}=2.66$ nM, $E_{max}=-35.95\%$) similar to ICI 174864 ([N,N-diallyl-Tyr $_1$,Aib $_2$,3,Leu $_5$]enkephaline) but with a 3.5-fold higher EC_{50} . In comparison, naltrindole was a neutral antagonist while its analog HS 378 was a partial inverse agonist ($E_{max}=-12.99\%$).

IT 172262-39-4 172262-40-7 178951-50-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inverse agonism by Dmt-Tic analogs and HS 378)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:288696 HCAPLUS

DOCUMENT NUMBER: 133:12871

TITLE: Opioid peptide analogs containing 2'-hydroxy,6'-methyltyrosine in place of Tyr $_1$ display greatly enhanced δ antagonist potency but unchanged μ agonist potency

AUTHOR(S): Berezowska, Irena; Lemieux, Carole; Nguyen, Thi M.
-D.; Chung, Nga N.; Schiller, Peter W.

CORPORATE SOURCE: Clinical Research Institute of Montreal, Montreal, QC,
H2W 1R7, Can.

SOURCE: Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (1999), Meeting Date 1998, 718-719. Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Akademiai Kiado: Budapest, Hung.

CODEN: 68WKAY

DOCUMENT TYPE: Conference

LANGUAGE: English

AB The authors report the syntheses and in vitro opioid activity profiles of the Hmt $_1$ -analogs of the δ antagonists TIP (H-Tyr-Tic-Phe-OH) and TIPP (H-Tyr-Tic-Phe-Phe-OH) and of the μ agonists TAPP (H-Tyr-D-Ala-Phe-Phe-NH $_2$) and DALDA (H-Tyr-D-Arg-Phe-Lys-NH $_2$). In vitro opioid activities of the compds. were determined in the μ -receptor-representative guinea pig ileum assay and in the δ receptor-representative mouse vas deferens (MVD) assay, and their μ and δ receptor affinities were measured in binding assays based on displacement of [3H]DAMGO and [3H]DSLET, resp., from rat brain membrane binding sites. The tripeptide H-Hmt-Tic-Phe-OH was an about 15 times more potent δ antagonist against the δ agonist DPDPE than its parent TIP, showing δ antagonist potency (MVD) and δ receptor binding affinity in the subnanomolar range. Furthermore, this compound showed greatly improved δ receptor selectivity as compared to TIP. The Hmt $_1$ -analog of the tetrapeptide TIPP, H-Hmt-Tic-Phe-Phe-OH, displayed very high δ antagonist potency in the MVD assay, comparable to that of H-Dmt-Tic-Phe-Phe-OH. In the binding assays, it showed slightly higher δ receptor affinity than H-Dmt-Tic-Phe-Phe-OH and 20-fold higher δ selectivity. Thus, [Hmt $_1$]TIPP ranks among the most potent and most specific δ opioid antagonists reported to date. Substitution of Hmt for Tyr $_1$ in the μ agonist peptides TAPP and DALDA resulted in μ -agonist potencies comparable to those of their resp. parent peptides. In conclusion, replacement of Tyr $_1$ in opioid peptides with Hmt produced a potency increase in the case of the δ antagonists but not in the case of the μ agonists.

IT 156219-37-3

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(opioid peptide analogs δ antagonist and μ agonist activity in relation to structure)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:288655 HCAPLUS

DOCUMENT NUMBER: 133:99680

TITLE: Tritium labelling of neuropeptides

AUTHOR(S): Toth, Geza; Farkas, Judit; Kertesz, Istvan; Tomboly, Csaba; Darula, Zsuzsanna; Peter, Antal

CORPORATE SOURCE: Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, Szeged, H-6701, Hung.

SOURCE: Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (

1999), Meeting Date 1998, 636-637. Editor(s):

Bajusz, Sandor; Hudecz, Ferenc. Akademiai Kiado:

Budapest, Hung.

CODEN: 68WKAY

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A report from a symposium presenting examples on the tritiation of labeled neuropeptides from synthetic precursor peptides. Catalytic dehalogenation with tritium gas produces radioactive peptides with high specific radioactivity, and with this method, the following new opioid peptides were radiolabeled: endomorphin II (μ agonist), N,N-(CH₃)₂-Dmt-Tic (δ antagonist), D-Ala²-D-Nle⁵-Met-enkephalin-Arg-Phe (κ 2 agonist), V-V-hemorphin 7 (Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe) and dermorphin (μ agonist). Precursor peptides were synthesized by solid phase peptide synthesis using the Boc method and the crude peptides were purified on RP-HPLC. The tritiation reaction was carried out on Pd/BaSO₄ catalyst with triethylamine to bind the proceeded acid in DMF as solvent with carrier free tritium gas. The crude radiolabeled peptides were purified by RP-HPLC using a radiodetector. Specific radioactivity of the tritiated peptides was then calculated from the radioactivity and the amount of the peptide. Finally, the tritiated peptides were stored as ethanolic solns. in liquid nitrogen and the stability of the ligands during storage and under binding conditions was investigated using rat brain membrane and HPLC.

IT 220045-96-5P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (opioid neuropeptide labeling with tritium and catalytic halogenation using synthetic precursor ligands)

IT 220045-93-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (opioid neuropeptide labeling with tritium and catalytic halogenation using synthetic precursor ligands)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:94013 HCAPLUS

DOCUMENT NUMBER: 132:245845

TITLE: Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists

AUTHOR(S): Page, D.; McClory, A.; Mischki, T.; Schmidt, R.; Butterworth, J.; St-Onge, S.; Labarre, M.; Payza, K.; Brown, W.

CORPORATE SOURCE: Department of Chemistry, AstraZeneca R and D Montreal, Saint-Laurent, QC, H4S 1Z9, Can.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000

), 10(2), 167-170
 CODEN: BMCLE8; ISSN: 0960-894X
 Elsevier Science Ltd.

PUBLISHER:
 DOCUMENT TYPE:
 LANGUAGE:

Journal
 English

AB A series of Dmt-Tic analogs with substitution on the Tic aromatic ring has been synthesized and evaluated for opioid receptor affinity and activation. Incorporation of large hydrophobic groups at position 7 of Tic did not greatly alter the δ opioid receptor binding affinities of the dipeptides whereas substitution at position 6 substantially diminished their affinity. These modified Dmt-Tic peptides showed binding affinities as low as 2.5 nM with ≤ 500 -fold selectivity for the δ vs. μ opioid receptor and proved to be δ receptor antagonists.

IT 262616-34-2P 262616-35-3P 262616-36-4P
 262616-37-5P 262616-38-6P 262616-39-7P
 262616-40-0P 262616-41-1P 262616-42-2P
 262616-43-3P 262616-44-4P 262616-45-5P
 262616-46-6P 262616-47-7P 262616-48-8P
 262616-49-9P 262616-50-2P 262616-51-3P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (novel Dmt-Tic dipeptide analogs as selective delta-opioid receptor antagonists)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:715597 HCAPLUS

DOCUMENT NUMBER: 132:73213

TITLE: Further Studies on the Dmt-Tic Pharmacophore:
 Hydrophobic Substituents at the C-Terminus Endow
 δ Antagonists To Manifest μ Agonism or μ
 Antagonism

AUTHOR(S): Salvadori, Severo; Guerrini, Remo; Balboni,
 Gianfranco; Bianchi, Clementina; Bryant, Sharon D.;
 Cooper, Peter S.; Lazarus, Lawrence H.


CORPORATE SOURCE: Department of Pharmaceutical Science and Biotechnology
 Center, University of Ferrara, Ferrara, I-441000,
 Italy

SOURCE: Journal of Medicinal Chemistry (1999),
 42(24), 5010-5019

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

GI



AB Twenty N- and/or C-modified Dmt-Tic analogs (I; R1=NH2, CH2NH2, heterocyclics; R2=CH2COOH, COOH, etc.) yielded similar Ki values with either [3H]DPDPE (δ agonist) or [3H]N,N(Me)2-Dmt-Tic-OH (δ antagonist). N-Methylation enhanced δ antagonism while N-piperidine-1-yl, N-pyrrolidine-1-yl, and N-pyrrole-1-yl were detrimental. Dmt-Tic-X (X = -NHNH2, -NHCH3, -NH-1-adamantyl, -NH-tBu, -NH-5-tetrazolyl) had high δ affinities (K_i = 0.16 to 1 nM) with variable μ affinities to yield nonselective or weakly μ -selective analogs. N,N-(Me)2Dmt-Tic-NH-1-adamantane exhibited dual δ and μ receptor affinities ($K_{i\delta}$ = 0.16 nM and $K_{i\mu}$ = 1.12 nM) and potent δ antagonism (pA_2 = 9.06) with μ agonism (IC_{50} = 16 nM). H-Dmt-BHTic-OH (methylene bridge between C α of Tic and carboxylate function) yielded a biostable peptide with high δ affinity (K_i = 0.85 nM) and δ antagonism (pA_2 = 8.85) without μ bioactivity. Dmt-Tic-Ala-X (X = -NHCH3, -OCH3, -NH-1-adamantyl, -NHtBu) exhibited high δ affinities (K_i = 0.06 to 0.2 nM) and elevated μ affinities (K_i = 2.5 to 11 nM), but only H-Dmt-Tic-Ala-NH-1-adamantane and H-Dmt-Tic-Ala-NHtBu yielded δ receptor antagonism (pA_2 = 9.29 and 9.16, resp.). Thus, Dmt-Tic with hydrophobic C-terminal substituents enhanced μ affinity to provide δ antagonists with dual receptor affinities and bifunctional activity.

IT 172262-39-4P 172262-40-7P 172262-47-4P
172262-48-5P 178951-49-0P 194857-80-2P
254101-66-1P 254101-75-2P 254101-77-4P
254101-78-5P 254101-80-9P 254101-82-1P
254101-84-3P 254101-86-5P 254101-88-7P
254101-90-1P 254101-92-3P 254101-94-5P
254101-96-7P 254101-98-9P 254102-00-6P
254102-01-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(studies on opioid pharmacophore, hydrophobic substituents at C-terminus endow δ antagonists to manifest μ agonism or μ antagonism)

IT 189093-95-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(studies on opioid pharmacophore, hydrophobic substituents at C-terminus endow δ antagonists to manifest μ agonism or μ antagonism)

IT 254102-02-8P 254102-03-9P 254102-06-2P
254102-07-3P 254102-09-5P 254102-11-9P
254102-12-0P 254102-13-1P 254102-17-5P
254102-21-1P 254102-25-5P 254102-26-6P
254102-27-7P 254102-28-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(studies on opioid pharmacophore, hydrophobic substituents at C-terminus endow δ antagonists to manifest μ agonism or μ antagonism)

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:667719 HCAPLUS

DOCUMENT NUMBER: 131:347049

TITLE: (2S,3R)TMT-L-Tic-OH is a potent inverse agonist at the human δ -opioid receptor

AUTHOR(S): Hosohata, Keiko; Burkey, Thomas H.; Alfaro-Lopez, Josua; Hruby, Victor J.; Roeske, William R.; Yamamura, Henry I.

CORPORATE SOURCE: Departments of Pharmacology, Biochemistry, Psychiatry and Chemistry, University of Arizona, Tucson, AZ,

85724, USA
 SOURCE: European Journal of Pharmacology (1999),
 380(1), R9-R10
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB: We examined the pharmacol. effect of β -methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid ((2S,3R)TMT-L-Tic-OH) on G protein activation in membranes prepared from Chinese Hamster Ovary cells transfected with cDNA of the human δ -opioid receptor. (2S,3R)TMT-L-Tic-OH inhibited G protein activation to 58% of basal with an EC₅₀ of 0.72 nM as determined by [35S]GTP γ S binding. These findings suggest that (2S,3R)TMT-L-Tic-OH is a highly potent inverse agonist at the human δ -opioid receptor.

IT 250331-76-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 ((2S,3R)TMT-L-Tic-OH is a potent inverse agonist at the human δ -opioid receptor)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:484863 HCAPLUS
 DOCUMENT NUMBER: 131:266894
 TITLE: The Opioid μ Agonist/ δ Antagonist
 DIPP-NH2[Ψ] Produces a Potent Analgesic Effect, No
 Physical Dependence, and Less Tolerance than Morphine
 in Rats

AUTHOR(S): Schiller, Peter W.; Fundytus, Marian E.; Merovitz,
 Lisa; Weltrowska, Grazyna; Nguyen, Thi M.-D.; Lemieux,
 Carole; Chung, Nga N.; Coderre, Terence J.

CORPORATE SOURCE: Laboratory of Chemical Biology and Peptide Research
 and Pain Mechanisms Laboratory, Clinical Research
 Institute of Montreal, Montreal, QC, H2W 1R7, Can.

SOURCE: Journal of Medicinal Chemistry (1999),
 42(18), 3520-3526
 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB: Opioid compds. with mixed μ agonist/ δ antagonist properties are expected to be analgesics with low propensity to produce tolerance and dependence. In an effort to strengthen the μ agonist component of the mixed μ agonist/ δ antagonist H-Tyr-Tic-Phe-Phe-NH₂ (TIPP-NH₂), analogs containing structurally modified tyrosine residues in place of Tyr¹ were synthesized. Among the prepared compds., H-Dmt-Tic-Phe-Phe-NH₂ (DIPP-NH₂; Dmt = 2',6'-dimethyltyrosine) and H-Dmt-Tic Ψ [CH₂NH]Phe-Phe-NH₂ (DIPP-NH₂[Ψ]) retained a mixed μ agonist/ δ antagonist profile, as determined in the guinea pig ileum and mouse vas deferens assays, whereas H-Tmt-Tic-Phe-Phe-NH₂ (Tmt = N,2',6'-trimethyltyrosine) was a partial μ agonist/ δ antagonist and H-Tmt-Tic Ψ [CH₂NH]Phe-Phe-NH₂ was a μ antagonist/ δ antagonist. DIPP-NH₂[Ψ] showed binding affinities in the subnanomolar range for both μ and δ receptors in the rat brain membrane binding assays, thus representing the first example of a balanced μ agonist/ δ antagonist with high potency. In the rat tail flick test, DIPP-NH₂[Ψ] given icv produced a potent analgesic effect (ED₅₀ = 0.04 μ g), being about 3 times more potent than morphine (ED₅₀ = 0.11 μ g). It produced less acute tolerance than morphine but still a certain level of chronic tolerance. Unlike morphine, DIPP-NH₂[Ψ] produced no phys. dependence whatsoever upon chronic administration at high doses (\leq 4.5 μ g/h) over a

7-day period. In conclusion, DIPP-NH2[Ψ] fulfills to a large extent the expectations based on the mixed μ agonist/ δ antagonist concept with regard to analgesic activity and the development of tolerance and dependence.

IT 160429-67-4P 160429-68-5P 245538-28-7P
245538-29-8P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(opioid μ agonist/ δ antagonist DIPP-NH2[Ψ] produces a potent analgesic effect and No phys. dependence and less tolerance than morphine in Rats in relation to structure)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 10 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:410445 HCAPLUS

DOCUMENT NUMBER: 131:214535

TITLE: Tritiation of delta opioid-receptor selective antagonist dipeptide ligands with extraordinary affinity containing 2',6'-dimethyltyrosine

AUTHOR(S): Kertesz, I.; Toth, G.; Balboni, G.; Guerrini, R.; Salvadori, S.

CORPORATE SOURCE: Institute of Biochemistry, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, H-6701, Hung.

SOURCE: Czechoslovak Journal of Physics (1999), 49(Suppl. 1, Pt. 2, 13th Radiochemical Conference, 1998), 887-892

CODEN: CZYPAO; ISSN: 0011-4626

PUBLISHER: Institute of Physics, Academy of Sciences of the Czech Republic

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Recently a new class of δ opioid antagonists has been discovered by using Tyr1-Tic2 sequence. The substitution of Tyr1 by Dmt (Dmt = 2',6'-dimethyltyrosine) resulted in a new analog H-Dmt-Tic-OH with enhanced affinity and selectivity. Peptides containing Tic at position 2 undergo spontaneous diketopiperazine formation in some solvents, and thus, losing some of their binding ability. To avoid this unwanted side reaction, the authors synthesized the N,N-di-Me analog [N,N(Me)2Dmt-Tic-OH], and it was more stable under storage conditions, but its δ affinity declined moderately. On this basis, the authors prepared the diiodinated analogs of these dipeptides. Catalytic dehalotritiation of precursors resulted in tritiated peptides. High specific radioactivity, 44.67 Ci/mmol with H-[3H2]Dmt-Tic-OH and 59.88 Ci/mmol with N,N(Me)2[3H2]Dmt-Tic-OH were achieved.

IT 220045-95-4P 220045-96-5P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of tritiated 2',6'-dimethyltyrosyl dipeptides as antagonists of δ -opioid receptor)

IT 172262-39-4 178951-49-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tritiated 2',6'-dimethyltyrosyl dipeptides as antagonists of δ -opioid receptor)

IT 220045-90-9P 220045-93-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tritiated 2',6'-dimethyltyrosyl dipeptides as antagonists of δ -opioid receptor)

IT 220045-92-1P 220045-94-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of tritiated 2',6'-dimethyltyrosyl dipeptides as antagonists of δ -opioid receptor)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 11 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:396671 HCAPLUS

DOCUMENT NUMBER: 131:200061

TITLE: Generation of new Dmt-Tic δ opioid antagonists:
N-alkylation

AUTHOR(S): Lazarus, Lawrence H.; Salvadori, Severo; Balboni,
Gianfranco; Guerrini, Remo; Bianchi, Clementina;
Cooper, Peter S.; Bryant, Sharon D.

CORPORATE SOURCE: NIEHS, Research Triangle Park, NC, 27707, USA

SOURCE: Peptides: Frontiers of Peptide Science, Proceedings of
the American Peptide Symposium, 15th, Nashville, June
14-19, 1997 (1999), Meeting Date 1997,
603-604. Editor(s): Tam, James P.; Kaumaya, Pravin T.
P. Kluwer: Dordrecht, Neth.

CODEN: 67UCAR

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A symposium with seven refs. A discussion of the opioid antagonist
properties of N-alkylated analogs of Tyr-Tic peptide was given.

IT 178951-49-0 178951-50-3 178951-51-4

178951-52-5 179091-74-8 194857-63-1

194857-70-0 194857-73-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)

(biol. activity of as δ opioid antagonists prepared via
N-alkylation of Dmt-Tic peptide analogs)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:396632 HCAPLUS

DOCUMENT NUMBER: 131:208606

TITLE: A new class of dipeptide derivatives that are potent
and selective δ opioid agonists

AUTHOR(S): Schiller, P. W.; Weltrowska, G.; Berezowska, I.;
Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes,
B. C.

CORPORATE SOURCE: Clinical Research Institute of Montreal, Montreal, QC,
H2W 1R7, Can.

SOURCE: Peptides: Frontiers of Peptide Science, Proceedings of
the American Peptide Symposium, 15th, Nashville, June
14-19, 1997 (1999), Meeting Date 1997,
514-516. Editor(s): Tam, James P.; Kaumaya, Pravin T.
P. Kluwer: Dordrecht, Neth.

CODEN: 67UCAR

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A new class of potent and selective δ -opioid agonists has been
developed by alteration of dipeptides having the general formula
H-Tyr-Tic-NH-(CH₂)_n-Ph. Structure-activity data are presented for 18
dipeptides (displacement of DAMGO vs. DSLET from rat brain membrane
binding sites).

IT 209786-77-6 209786-79-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(dipeptide derivs. that are potent and selective δ opioid
agonists)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 13 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:1815 HCAPLUS

DOCUMENT NUMBER: 130:139633

TITLE: Synthesis of 2',6'-dimethyltyrosine containing tritiated delta opioid-receptor selective antagonist dipeptide ligands with extraordinary affinity

AUTHOR(S): Kertesz, I.; Balboni, G.; Salvadori, S.; Lazarus, L. H.; Toth, G.

CORPORATE SOURCE: Institute of Biochemistry, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, H-6701, Hung.

SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals (1998), 41(12), 1083-1091

CODEN: JLCRD4; ISSN: 0362-4803

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new class of δ -opioid antagonists was recently discovered in which the sequence Tyr-Tic was used as a message domain. The substitution of Tyr1 by Dmt (Dmt = 2',6'-dimethyltyrosine) enhanced the δ selectivity and antagonist activity. The excellent activity of these ligands was the reason for synthesizing the corresponding tritiated derivs. Peptides containing Tic (Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) at position 2 undergo spontaneous diketopiperazine formation in some solvents, with a reduction in opioid activity. To avoid this side-reaction, the N,N-di-Me analog [N,N(Me)2-Dmt-Tic-OH] was synthesized and it was found to be stable. Thus, diiodinated forms of H-Dmt-Tic-OH and N,N(Me)2-Dmt-Tic-OH were prepared to undergo the catalytic dehalotritiation step. Tritiated dipeptides of high specific radioactivity were obtained: 44.67 Ci/mmol for [3H]Dmt-Tic-OH and 59.88 Ci/mmol for [3H]N,N(Me)2-Dmt-Tic-OH.

IT 220045-95-4P 220045-96-5P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis of dipeptides containing tritiated dimethyltyrosines as δ -opioid receptor antagonists)

IT 172262-39-4 178951-49-0

RL: RCT (Reactant); RACT (Reactant or reagent) (synthesis of dipeptides containing tritiated dimethyltyrosines as δ -opioid receptor antagonists)

IT 220045-90-9P 220045-93-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (synthesis of dipeptides containing tritiated dimethyltyrosines as δ -opioid receptor antagonists)

IT 220045-92-1P 220045-94-3P

RL: SPN (Synthetic preparation); PREP (Preparation) (synthesis of dipeptides containing tritiated dimethyltyrosines as δ -opioid receptor antagonists)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:597921 HCAPLUS

DOCUMENT NUMBER: 129:339945

TITLE: Subtleties of structure- δ agonist vs. δ antagonist relationships of opioid dipeptide derivatives

AUTHOR(S): Schiller, P. W.; Weltrowska, G.; Bolewska-Pedyczak, E.; Nguyen, T. M-D.; Lemieux, C.; Chung, N. N.

CORPORATE SOURCE: Laboratory of Chemical Biology and Peptide Research,

Clinical Research Institute of Montreal, Montreal, QC, H2W 1R7, Can.

SOURCE: Peptides 1996, Proceedings of the European Peptide Symposium, 24th, Edinburgh, Sept. 8-13, 1996 (1998), Meeting Date 1996, 785-786. Editor(s): Ramage, Robert; Epton, Roger. Mayflower Scientific: Kingswinford, UK.
CODEN: 66RCA5

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Recently, the authors reported that the dipeptide derivative H-Tyr-Tic-NH-(Ch₂)₂-Ph represents a new prototype of a moderately potent δ -selective opioid agonist. In the present paper, the authors describe how subtle structural modifications of this parent structure led to a potent and selective δ agonist, δ antagonists and mixed μ agonist/ δ antagonists. Compds. were synthesized by solution methods and their opioid activity profiles were determined in vitro in the guinea pig ileum and mouse vas deferens bioassays and the rat brain membrane receptor binding assays.

IT 215596-98-8 215597-26-5 215597-37-8
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(subtleties of structure- δ agonist vs. δ antagonist relationships of opioid dipeptide derivs.)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 15 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:507698 HCAPLUS

DOCUMENT NUMBER: 129:245476

TITLE: Conformationally constrained opioid peptide analogs with novel activity profiles

AUTHOR(S): Schiller, Peter W.; Schmidt, Ralf; Weltrowska, Grazyna; Berezowska, Irena; Nguyen, Thi M.-D.; Dupuis, Sebastien; Chung, Nga N.; Lemieux, Carole; Wilkes, Brian C.; Carpenter, Katharine A.

CORPORATE SOURCE: Laboratory of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, QC, H2W 1R7, Can.

SOURCE: Letters in Peptide Science (1998), 5(2-3), 209-214
CODEN: LPSCEM; ISSN: 0929-5666

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Novel conformationally constrained opioid peptide analogs, having properties as δ antagonist, mixed μ agonist/ δ antagonist or δ agonist, were developed. TIP(P)-related δ antagonists showed unprecedented δ antagonist potency and δ receptor selectivity, and may have potential for use in analgesia in combination with μ agonists. A definitive model of their δ receptor-bound conformation was developed. Three prototype mixed μ agonist/ δ antagonists were discovered. They represent the only known compds. with this pharmacol. profile and, as expected, one of them was shown to be a potent analgesic and to produce no dependence and less tolerance than morphine. Novel dipeptide derivs. turned out to be potent and selective δ agonists. Because of their low mol. weight and lipophilic character, these compds. may cross the blood-brain barrier and, thus, may have potential as centrally acting analgesics.

IT 156219-37-3 160429-67-4 160429-68-5
172262-39-4 173927-99-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(activity profiles of conformationally constrained opioid peptide
analogs)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 16 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:479553 HCAPLUS

DOCUMENT NUMBER: 129:95725

TITLE: Preparation of dipeptide derivatives for treatment of
pain

INVENTOR(S): Schiller, Peter

PATENT ASSIGNEE(S): Astra AB (Publ), Swed.

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828327	A1	19980702	WO 1997-SE2156	19971218 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9855808	A1	19980717	AU 1998-55808	19971218 <--
AU 721131	B2	20000622		
EP 946588	A1	19991006	EP 1997-952145	19971218 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
NZ 336026	A	20010223	NZ 1997-336026	19971218
JP 2001507026	T2	20010529	JP 1998-528696	19971218
US 6150335	A	20001121	US 1998-43881	19980401
NO 9903069	A	19990621	NO 1999-3069	19990621 <--
PRIORITY APPLN. INFO.:			SE 1996-4789	A 19961220
			WO 1997-SE2156	W 19971218
OTHER SOURCE(S):		MARPAT 129:95725		
GI				



AB Dipeptide derivs. I [R1, R2 = independently H, Me(CH2)n, Ph(CH2)m, cyclopropylmethyl, allyl; R3-R6 = H; R3 = C1-6 alkyl, R4-R6 = H; R3 = R6 = C1-6 alkyl, R4 = R5 = H; R3 = R5 = R6 = H, R4 = F, Cl, Br, iodo, OH, NO2,

NH₂; R₇ = (un)substituted 2-phenylethyl or 2-cyclohexylethyl; n = 0-12; m = 1-3] are claimed for the manufacture of a medicament for the treatment of pain. The compds. are δ opioid agonists and thus useful in the treatment of pain without the requirement of co-application of a μ opioid agonist. Thus, amidation of Boc-Tic-OH (Boc = Me₃CO₂C; Tic = L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) with 2,2-diphenylethylamine, deprotection, peptide coupling with Boc-Tyr(Boc)-OH, and final deprotection gave desired dipeptide derivative H-Tyr-Tic-NHCH₂CHPh₂ (II). II and related dipeptide derivs. are selective δ opioid agonists, with II having K_i = 0.981 nM in a δ opioid receptor assay.

IT 209786-71-0P 209786-77-6P 209786-79-8P
209786-80-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dipeptide derivs. for treatment of pain)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 17 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:102445 HCAPLUS

DOCUMENT NUMBER: 128:226374

TITLE: Rational design of dynorphin A analogs with δ -receptor selectivity and antagonism for δ - and κ -receptors

AUTHOR(S): Guerrini, Remo; Capasso, Anna; Marastoni, Mauro; Bryant, Sharon D.; Cooper, Peter S.; Lazarus, Lawrence H.; Temussi, Piero A.; Salvadori, Severo

CORPORATE SOURCE: Department of Pharmaceutical Sciences and Biotechnology Center, University of Ferrara, Ferrara, I-44100, Italy

SOURCE: Bioorganic & Medicinal Chemistry (1998), 6(1), 57-62

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Substitution of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in place of Gly₂ in dynorphin A-(1-13)-NH₂ and -(1-11)-NH₂ (DYN) analogs (1 and 2) decreased the affinity to the κ , δ , and μ receptors, and κ selectivity. The analog [D-Ala₂, des-Gly₃]DYN (4), a chimera between deltorphin/dermorphin N-terminal tripeptide and DYN, was virtually inactive for κ -sites while the affinities for δ - and μ -receptors remained essentially unchanged. The doubly substituted analog [2',6'-dimethyl-L-tyrosine (Dmt₁)-Tic₂]DYN (3) exhibited high δ -affinity (K_i=0.39 nM) while μ - and κ -affinities were only an order of magnitude less (4-5 nM). Bioactivity of [Tic₂]DYN peptides (1-3) on guinea-pig ileum and rabbit jejunum revealed potent δ - and κ -antagonism, while the δ agonist potency of 4 was comparable to DYN. Thus, conversion from a κ -agonist to antagonist occurred with the inclusion of Tic into DYN analogs, similar to the appearance of antagonist properties with δ - and μ -opioid agonists containing a Tic₂ residue.

IT 204764-01-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(rational design of dynorphin A analogs with δ -receptor selectivity and antagonism for δ - and κ -receptors)

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 18 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:20189 HCAPLUS
 DOCUMENT NUMBER: 128:162532
 TITLE: The stereochemical requirements of the novel
 δ -opioid selective dipeptide antagonist TMT-TIC
 AUTHOR(S): Liao, Subo; Lin, Jun; Shenderovich, Mark D.; Han,
 Yinglin; Hasohata, Keiko; Davis, Peg; Qiu, Wei;
 Porreca, Frank; Yamamura, Henry I.; Hruby, Victor J.
 CORPORATE SOURCE: Department of Chemistry, The University of Arizona,
 Tucson, AZ, 85721, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1997
), 7(23), 3049-3052
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Five conformationally constrained dipeptide TMT-L-Tic analogs have been
 synthesized and evaluated for their bioactivity using in vitro bioassays.
 The most potent and selective analog (2S,3R)-TMT-L-Tic showed 9 nM binding
 affinity and 4000-fold selectivity for the δ vs. μ opioid
 receptor. The lowest-energy conformation of (2S,3R)-TMT-L-Tic is
 suggested to be bioactive one in which the χ_1 torsional angle is trans
 for TMT and gauche (+) for Tic.

IT 202860-53-5P 202860-54-6P 202860-55-7P
 202860-56-8P 202860-57-9P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
 (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation); PROC (Process)

(stereochem. requirements of the novel δ -opioid selective
 dipeptide antagonist TMT-TIC)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 19 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:594750 HCAPLUS
 DOCUMENT NUMBER: 127:248425
 TITLE: Isoquinolines useful as analgesics
 INVENTOR(S): Dimaio, John; Wang, Wuyi
 PATENT ASSIGNEE(S): Astra AB, Swed.; Dimaio, John; Wang, Wuyi
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731940	A1	19970904	WO 1997-SE315	19970225 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			
	DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,			
	LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,			
	RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,			
	YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,			
	IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,			
	MR, NE, SN, TD, TG			
CA 2244219	AA	19970904	CA 1997-2244219	19970225 <--
AU 9721090	A1	19970916	AU 1997-21090	19970225 <--
AU 722032	B2	20000720		
CN 1211990	A	19990324	CN 1997-192558	19970225 <--
EP 914332	A1	19990512	EP 1997-906381	19970225 <--
EP 914332	B1	20020508		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO


BR 9707767	A	19990727	BR 1997-7767	19970225 <--
JP 2000506138	T2	20000523	JP 1997-530865	19970225
NZ 331119	A	20000526	NZ 1997-331119	19970225
AT 217322	E	20020515	AT 1997-906381	19970225
US 6034097	A	20000307	US 1997-930867	19971006 <--
NO 9803945	A	19981006	NO 1998-3945	19980827 <--

PRIORITY APPLN. INFO.:

SE 1996-769 A 19960228
WO 1997-SE315 W 19970225

OTHER SOURCE(S): MARPAT 127:248425

GI



- AB Peptidomimetic isoquinolines I [X = CH₂NHCO, CH₂NHCO₂, CONH, CH₂NH; L = (un)substituted alkyl; R = 3-aryl- or 3-aralkyl-2-pyrrolidinyl or -2-piperidinyl, 1-[(un)substituted amino]alkyl or -aralkyl; R₁ = aryl, aralkyl, alkyl; R₂ = alkyl, H, OH, halo, SH, NO₂, NH₂, alkylamino, NH:C(NH₂), NH:C(NH₂)NH, CO₂H or carbalkoxy] were prepared as analgesics. Thus, 2-[2-guanidino-3-(4-hydroxy-2,6-dimethylphenyl)propionyl]-1,2,3,4-tetrahydroisoquinoline-3-S-carboxylic acid (2-R-hydroxy-3-phenylpropyl)amide bistrifluoroacetate was prepared and assayed for analgesic activity (K_{1μ} = 2.03±0.37, K_{iδ} = 0.56±0.09, and K_{1κ} = 276.6±13.6 nM).
- IT 195831-57-3P 195831-71-1P 195831-73-3P
195831-77-7P 195831-82-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(isoquinolines useful as analgesics)
- IT 195832-13-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(isoquinolines useful as analgesics)
- IT 195831-53-9P 195831-55-1P 195831-59-5P
195831-61-9P 195831-63-1P 195831-65-3P
195831-67-5P 195831-69-7P 195831-75-5P
195831-78-8P 195831-80-2P 195831-84-6P
195831-86-8P 195831-88-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(isoquinolines useful as analgesics)

L15 ANSWER 20 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:565015 HCAPLUS

DOCUMENT NUMBER: 127:214595

TITLE: Evolution of the Dmt-Tic Pharmacophore: N-Terminal
Methylated Derivatives with Extraordinary δ
Opioid Antagonist Activity

AUTHOR(S): Salvadori, Severo; Balboni, Gianfranco; Guerrini,
Remo; Tomatis, Roberto; Bianchi, Clementina; Bryant,
Sharon D.; Cooper, Peter S.; Lazarus, Lawrence H.

CORPORATE SOURCE: Department of Pharmaceutical Science and Biotechnology
Center, University of Ferrara, Ferrara, 44100, Italy

SOURCE: Journal of Medicinal Chemistry (1997),

40(19), 3100-3108
 CODEN: JMCMAR; ISSN: 0022-2623
 American Chemical Society

PUBLISHER:
 DOCUMENT TYPE:
 LANGUAGE:

Journal
 English

AB The δ opioid antagonist H-Dmt-Tic-OH (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydro-3-isoquinoline-3-carboxylic acid) exhibits extraordinary δ receptor binding characteristics [$K_{i\delta} = 0.022$ nM; $K_{i\mu}/K_{i\delta} = 150\ 000$] and δ antagonism ($pA_2 = 8.2$; $K_e = 5.7$ nM). A change in chirality of Dmt at C α curtailed δ receptor parameters, while replacement of its α -amino function by a Me group led to inactivity; Tyr-Tic analogs weakly interacted with δ receptors. N-Alkylation of H-Dmt-Tic-OH and H-Dmt-Tic-Ala-OH with Me groups produced potent δ opioid ligands with high δ receptor binding capabilities and enhanced δ antagonism: (i) N-Me-Dmt-Tic-OH had high δ opioid binding ($K_{i\delta} = 0.2$ nM), elevated δ antagonism on mouse vas deferens (MVD) ($pA_2 = 8.5$; $K_e = 2.8$ nM), and nondetectable μ activity with guinea pig ileum (GPI). (ii) N,N-Me₂-Dmt-Tic-OH was equally efficacious in δ receptor binding ($K_{i\delta} = 0.12$ nM; $K_{i\mu}/K_{i\delta} = 20\ 000$), but δ antagonism rose considerably ($pA_2 = 9.4$; $K_e = 0.28$ nM) with weak μ antagonism ($pA_2 = 5.8$; $K_e = 1.58$ μ M; GPI/MVD = 1:5640). N-Me- and N,N-Me₂-Dmt-Tic-Ala-OH also augmented δ opioid receptor binding, such that N,N-Me₂-Dmt-Tic-Ala-OH demonstrated high affinity ($K_{i\delta} = 0.0755$ nM) and selectivity ($K_{i\mu}/K_{i\delta} = 20\ 132$) with exceptional antagonist activity on MVD ($pA_2 = 9.6$; $K_e = 0.22$ nM) and weak antagonism on GPI ($pA_2 = 5.8$; $K_e = 1.58$ μ M; GPI/MVD = 1:7180). Although the amidated dimethylated dipeptide analog had high $K_{i\delta}$ (0.31 nM) and excellent antagonist activity ($pA_2 = 9.9$; $K_e = 0.12$ nM), the increased activity toward μ receptors in the absence of a free acid function at the C-terminus revealed a modest δ selectivity ($K_{i\mu}/K_{i\delta} = 1\ 655$) and somewhat comparable bioactivity (GPI/MVD = 4500). Thus, the data demonstrate that N,N-(Me)₂-Dmt-Tic-OH and N,N-Me₂-Dmt-Tic-Ala-OH retained high δ receptor affinities and δ selectivities and acquired enhanced potency in pharmacol. bioassays on MVD greater than that of other peptide or non-peptide δ antagonists.

IT 189094-51-7P 194857-52-8P 194857-55-1P
 194857-60-8P 194857-61-9P 194857-62-0P
 194857-64-2P 194857-66-4P 194857-69-7P
 194857-71-1P 194857-72-2P 194857-74-4P
 194857-76-6P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of dimethyltyrosyl isoquinolinecarboxylate derivs. as δ opioid antagonists)

IT 172262-39-4 172262-40-7 172262-47-4

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(preparation of dimethyltyrosyl isoquinolinecarboxylate derivs. as δ opioid antagonists)

IT 189093-95-6P 194857-79-9P 194857-81-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dimethyltyrosyl isoquinolinecarboxylate derivs. as δ opioid antagonists)

L15 ANSWER 21 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:455179 HCAPLUS

DOCUMENT NUMBER: 127:171672

TITLE: Design and solution structure of a partially rigid

opioid antagonist lacking the basic center. Models of antagonism

AUTHOR(S): Crescenzi, Orlando; Fraternali, Franca; Picone, Delia; Tancredi, Teodorico; Balboni, Gianfranco; Guerrini, Remo; Lazarus, Lawrence H.; Salvadori, Severo; Temussi, Piero A.

CORPORATE SOURCE: Dipartimento di Chimica, Universita di Napoli Federico II, Naples, I-80134, Italy

SOURCE: European Journal of Biochemistry (1997), 247(1), 66-73
CODEN: EJBCAI; ISSN: 0014-2956

PUBLISHER: Springer

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To discriminate between two general models of antagonism (participation and allosteric), an opioid antagonist lacking the basic nitrogen of tyramine was designed and characterized. Cyclo-[Tyr(Me)₂-Tic-], the diketopiperazine of 2,6-dimethyltyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, is a partially rigid opioid antagonist; its pA₂ (5.8) is one smaller than that of N,N-bisallyl-enkephalin but it has a very high binding affinity (10 nM) and has a δ selectivity (66 with respect to the binding to μ receptors) higher than that of naltrindole. The conformational state of this diketopiperazine, studied under a variety of solvent and temperature conditions by NMR and mol. dynamics, can be described in terms of only three conformers whose relative populations vary widely with solvent. Only one of the three conformers, characterized by a 90° arrangement of the aromatic rings of Tyr(Me)₂ and Tic similar to those of rigid agonists and of the bioactive conformation of the corresponding linear antagonist, is consistent with the antagonist activity. This finding favors the participation model among the general mechanisms proposed to explain antagonism. Due to the simple composition of the conformational mixture and to the rigidity of the mol., it is possible to propose a quant. explanation for the discrepancy between the very high binding affinity (10 nM) and the fairly small in mouse vas deferens value (1.5 μ M).

IT 178951-47-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(structure of a partially rigid opioid antagonist lacking the basic center)

IT 193897-93-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(structure of a partially rigid opioid antagonist lacking the basic center)

IT 172262-40-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(structure of a partially rigid opioid antagonist lacking the basic center design and solution)

L15 ANSWER 22 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:101287 HCAPLUS

DOCUMENT NUMBER: 126:288045

TITLE: Opioid diketopiperazines. Synthesis and activity of a prototypic class of opioid antagonists

AUTHOR(S): Balboni, Gianfranco; Guerrini, Remo; Salvadori, Severo; Tomatis, Roberto; Bryant, Sharon D.; Bianchi, Clementina; Attila, Martti; Lazarus, Lawrence H.

CORPORATE SOURCE: Biotechnology Center, Univ. Ferrara, Ferrara, I-44100, Italy

SOURCE: Biological Chemistry (1997), 378(1), 19-29
CODEN: BICHF3; ISSN: 1431-6730

PUBLISHER: de Gruyter

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Discovery of high affinity and ultrasensitive δ opioid dipeptide antagonists composed of 2',6'-dimethyl-L-tyrosine (Dmt) and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) served as the basis for the conformationally restricted diketopiperazine cyclo(Dmt-Tic) and related open chain analogs. These peptides primarily bind to δ -opioid receptors: c(Dmt-Tic) displayed 30- to 50-fold higher δ affinity ($K_{i\delta}$) than its diastereomeric analogs and more than 4000-fold greater than its Tyr cognate; all of the c(Tyr-Tic) analogs were essentially inactive; c[(N-methyl)Dmt-Tic] lost 5-fold in $K_{i\delta}$, while K_{iM} , increased 10-fold to yield a nonselective peptide; and the c(Dmt-Phe) series exhibited considerably reduced binding which indicated a synergism between Dmt and Tic in the binding mechanism. Whereas acetyl-Dmt-Tic linear peptides weakly interacted with opioid receptors, Ac-Dmt-Tic-NH₂, exhibited better δ antagonist activity than c(Dmt-Tic) and greater δ receptor selectivity ($K_{i\mu}/K_{i\delta} = 570$). A 3 point attachment hypothesis for the interaction between c(Dmt-Tic) and the δ receptor was proposed: hydrophobicity imparted by the aromatic rings and the Me groups of Dmt, H bonding through the tyramine OH group, and cation- π interactions were suggested as contributing factors in binding the diketopiperazine in the receptor pocket. Although c(Dmt-Tic) exhibited a weak antagonist activity with mouse vas deferens, this diketopiperazine may provide a scaffolding for the formation of more potent antagonists for potential therapeutic applications.

IT 178951-45-6P 178951-46-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and activity of prototypic diketopiperazine δ -opioid antagonists)

IT 178951-47-8P 178951-48-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and activity of prototypic diketopiperazine δ -opioid antagonists)

IT 189094-01-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and activity of prototypic diketopiperazine δ -opioid antagonists)

IT 189093-93-4P 189093-95-6P 189094-05-1P

189094-07-3P 189094-51-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and activity of prototypic diketopiperazine δ -opioid antagonists)

L15 ANSWER 23 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:714329 HCAPLUS

DOCUMENT NUMBER: 126:26958

TITLE: Development of potent opioid δ antagonists and mixed μ agonist/ δ antagonists

AUTHOR(S): Schiller, P. W.; Schmidt, R.; Wilkes, B. C.; Weltrowska, G.; Nguyen, T. M. -D.; Chung, N. N.; Lemieux, C.

CORPORATE SOURCE: Laboratory Chemical Biology and Peptide Research, Clinical Research Institute Montreal, Montreal, QC, H2W 1R7, Can.

SOURCE: Peptides: Biology and Chemistry, Proceedings of the Chinese Peptide Symposium, 3rd, Beijing, June 13-17,

1994 (1995), Meeting Date 1994, 140-143.
 Editor(s): Lu, Gui-Shen; Tam, James P.; Du, Yu-Cang.
 ESCOM: Leiden, Neth.
 CODEN: 63QWA5

DOCUMENT TYPE: Conference
 LANGUAGE: English

AB An analog of TIPP (Tyr-Tic-Phe-Phe) is reported which is a mixed μ agonist/ δ antagonist with both greatly enhanced μ agonist potency and still very high δ antagonist activity.

IT 160429-67-4 161669-02-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (potent opioid δ antagonists and mixed μ agonist/ δ antagonists)

L15 ANSWER 24 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:639557 HCAPLUS

DOCUMENT NUMBER: 126:1296

TITLE: Novel opioid peptide analogs with mixed μ agonist/ δ antagonist properties

AUTHOR(S): Schiller, P. W.; Weltrowska, G.; Nguyen, T. M. -D.; Lemieux, C.; Chung, N. N.

CORPORATE SOURCE: Clinical Research Institute Montreal, Montreal, QC, H2W 1R7, Can.

SOURCE: Peptides 1994, Proceedings of the European Peptide Symposium, 23rd, Braga, Port., Sept. 4-10, 1994 (1995), Meeting Date 1994, 632-633. Editor(s): Maia, Hernani L. S. ESCOM: Leiden, Neth.
 CODEN: 63MBAO

DOCUMENT TYPE: Conference
 LANGUAGE: English

AB In an effort to strengthen the agonist component of TIPP-NH₂, the authors substituted 2',6'-dimethyltyrosine (Dmt) for Tyr¹. The resulting compound, H-Dmt-Tic-Phe-Phe-NH₂ (DIPP-NH₂), displayed a potent agonist effect in the GPI assay. This effect was reversed by a low dose of naloxone (K_e = 2.42 nmol dm⁻³), indicating that it was mediated by receptors. In the MVD assay DIPP-NH₂ was a potent antagonist with a value in the subnanomolar range. In comparison with the parent compound TIPP-NH₂, DIPP-NH₂ showed 65 times higher receptor affinity and 25 times higher affinity in the opioid receptor binding assays. Reduction of the peptide bond between Tic and Phe in DIPP-NH₂ resulted in a pseudopeptide analog, H-Tyr-Tic[CH₂-NH]Phe-Phe-NH₂, which was an agonist with twice the potency of DIPP-NH₂ in the GPI assay and again showed a low K_e value (1.25 nmol dm⁻³) for naloxone as antagonist.

IT 160429-67-4 160429-68-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (novel opioid peptide analogs with mixed μ agonist/ δ antagonist properties)

L15 ANSWER 25 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:462678 HCAPLUS

DOCUMENT NUMBER: 125:158369

TITLE: Dmt-TIC-OH, a highly selective and potent δ -opioid dipeptide receptor antagonist after systemic administration in the mouse

AUTHOR(S): Capasso, Anna; Guerrini, Remo; Balboni, Gianfranco; Sorrentino, Ludovico; Temussi, Pierandrea; Lazarus, Lawrence H.; Bryant, Sharon D.; Salvadori, Severo

CORPORATE SOURCE: Sch. Pharmacy, Univ. Salerno, Italy

SOURCE: Life Sciences (1996), 59(8), PL 93-PL 98

CODEN: LIFSAK; ISSN: 0024-3205

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Dmt-Tic-OH (DTHO) and Dmt-Tic-Ala-OH (DTAHO), effective antagonists, in vitro, represent new potent opioid dipeptides for the δ -opioid receptor ($K_{i\delta}$ of 0.022 nM and a selectivity, $K_{i\mu}/K_{i\delta}$, of 150,000 for DTHO; $K_{i\delta}$ of 0.285 nM and a selectivity $K_{i\mu}/K_{i\delta}$, of 20,4 for DTAHO). In the present study we considered the pharmacol. activity of these two new δ opioid peptide receptor antagonists in vivo. Therefore, we have evaluated their possible antagonistic activity against the antinociception induced by the highly selective δ opioid receptor agonist, [D-Ala2]deltorphin II (DEL). Furthermore, these two δ opioid peptide receptor antagonists were injected centrally or peripherally in order to assess their ability to act also after systemic administration. Concurrent i.c.v. injection of DTHO or DTAHO (0.5-1.0-2.0 nM) with DEL (5 nmol) induced a significant reduction of DEL antinociception. By contrast, while DTHO (10-20-40 mg/kg) administered peripherally (i.p., s.c. or i.v.) was also able to reduce DEL antinociception, DTAHO failed. The present results indicate that DTHO is the first opioid dipeptide with δ antagonist activity after systemic administration and it could be important in clin. and therapeutic applications.

IT 172262-39-4 172262-47-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmacol. activity of δ opioid receptor antagonists Dmt-Tic-OH and Dmt-Tic-Ala-OH)

L15 ANSWER 26 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:447008 HCAPLUS

DOCUMENT NUMBER: 125:105145

TITLE: Ultraselective δ -opioid mimetic peptides containing dimethyltyrosine and tetrahydroisoquinoline carboxylate and pharmacological and therapeutic uses thereof

INVENTOR(S): Lazarus, Lawrence H.; Salvadori, Severo; Temussi, Piero Andrea

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616982	A2	19960606	WO 1995-US15510	19951130 <--
WO 9616982	A3	19961024		
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5780589	A	19980714	US 1994-347531	19941130 <--
AU 9644639	A1	19960619	AU 1996-44639	19951130 <--
PRIORITY APPLN. INFO.:			US 1994-347531	19941130
			WO 1995-US15510	19951130

OTHER SOURCE(S): MARPAT 125:105145

AB Novel opioid mimetic dipeptides, tripeptides and cyclic peptides exhibit enhanced affinity and selectivity for δ -opioid receptors. The

peptides are represented by the formulas L/D-Dmt-L-/D-Tic-R', L/D-R"-Dmt-L/D-Tic-R'; L/D-Dmt-L-/D-Tic-R-R'; L/D-R"-Dmt-L/D-Tic-R-R'; and cyclic (L/D-Dmt-L/D-Tic) wherein Dmt is 2',6'-dimethyl-L/D-tyrosine, Tic is L/D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, R is a natural or unusual aliphatic amino residue, R' is a functional group at the carboxyl terminus of the peptide and R" is a functional group at the amino terminus of the peptide. Pharmacol. and therapeutic compns. are also provided.

IT 172262-39-4 172262-40-7 172262-41-8
172262-42-9 172262-47-4 172262-48-5
172339-67-2 172339-68-3 178951-42-3
178951-45-6 178951-46-7 178951-47-8
178951-48-9 178951-49-0 178951-50-3
178951-51-4 178951-52-5 179091-74-8
179091-75-9

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(δ -opioid mimetic; ultraselective δ -opioid mimetic peptides containing dimethyltyrosine and tetrahydroisoquinoline carboxylate and pharmacol. and therapeutic uses thereof)

L15 ANSWER 27 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:431375 HCAPLUS

DOCUMENT NUMBER: 125:87219

TITLE: Preparation of new peptide derivatives with delta opioid receptor antagonist or mixed mu agonist/delta antagonist effects

INVENTOR(S): Schiller, Peter

PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9606855	A1	19960307	WO 1995-SE918	19950810 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9506561	A	19960229	ZA 1995-6561	19950804 <--
CA 2197566	AA	19960307	CA 1995-2197566	19950810 <--
AU 9534016	A1	19960322	AU 1995-34016	19950810 <--
AU 695175	B2	19980806		
EP 776332	A1	19970604	EP 1995-930752	19950810 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10504837	T2	19980512	JP 1995-508658	19950810 <--
US 5811400	A	19980922	US 1995-532688	19951006 <--
FI 9700823	A	19970227	FI 1997-823	19970227 <--
NO 9700889	A	19970227	NO 1997-889	19970227 <--
PRIORITY APPLN. INFO.:			SE 1994-2880	19940830
			WO 1995-SE918	19950810
OTHER SOURCE(S):		MARPAT 125:87219		
GI				



AB Compds. of formula [I; R1 = H, Me(CH2)n (wherein n = 0-12), CH2CH2Ph, cyclopropylmethyl, allyl, H-Arg; R2 = H, Me(CH2)n (wherein n = 0-12), cyclopropylmethyl, allyl; R3 - R6 = H; or R4 = R5 = H and R3, R6 = C1-6 alkyl; R3 = R5 = R6 = H and R4 = F, Cl, Br, OH, or NO2; R7 = CO, CH2; R8 = H, C1-12 alkyl, aryl-C1-12 alkyl; R9 = linear or branched C1-12 alkyl, aryl-C1-2 alkyl, C1-12 alkyl-linked to a heterocyclic moiety], which show high potency as δ antagonists or a mixed μ agonist/ δ antagonist properties with total lack of μ antagonist properties, have a low mol. weight and are highly lipophilic, facilitate passage across the brain blood-barrier, and are useful in therapy, especially as analgesics and as immunosuppressive agents, are prepared. Thus, Boc-Tic-OH (Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid residue) was treated with iso-Bu chloroformate in THF at -15° for 3-4 min, coupled with H2N(CH2)3Ph at -15° for 30 min, and stirred with CF3CO2H containing 3% thioanisole under ice-cooling to give 95% H-Tic-NH(CH2)3Ph.CF3CO2H. The latter compound was similarly coupled with Boc-Tyr(Boc)-OH in the presence of N-methylmorpholine and deprotected with CF3CO2H to give, after HPLC purification, 80% H-Tyr-Tic-NH(CH2)3Ph. All compds. showed δ -antagonist properties and no μ antagonist activity in the guinea pig ileum assay at concns. as high as 10 μ M and were either partial or full μ agonists in the guinea pig ileum assay. In particular, H-Dmt-Tic-NHCH2CH2Q (Q = CH2Ph, cyclohexyl, 3-indolyl; Dmt = 2',6'-dimethyltyrosine) were potent mixed μ agonist/ δ antagonists.

IT 178752-43-7P 178752-50-6P 178752-53-9P
178752-57-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of new peptide derivs. with δ opioid receptor antagonist or mixed μ agonist/ δ antagonist effects as analgesics and immunosuppressants)

L15 ANSWER 28 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:196729 HCAPLUS
DOCUMENT NUMBER: 124:261755
TITLE: Preparation of opioid peptide analogs as δ opioid receptor antagonists
INVENTOR(S): Schiller, Peter
PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```

-----
WO 9535316      A1  19951228      WO 1995-SE721      19950614 <--
W:  AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
    GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
    MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
    TM, TT
RW:  KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
    LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
    SN, TD, TG
ZA 9504311      A    19960122      ZA 1995-4311      19950526 <--
CA 2192484      AA   19951228      CA 1995-2192484   19950614 <--
AU 9528114      A1   19960115      AU 1995-28114     19950614 <--
AU 691630       B2   19980521
EP 777682       A1   19970611      EP 1995-923629    19950614 <--
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 10501807     T2   19980217      JP 1995-502047    19950614 <--
US 5733881      A    19980331      US 1995-507370    19950822 <--
NO 9605457      A    19961218      NO 1996-5457      19961218 <--
FI 9605116      A    19961219      FI 1996-5116      19961219 <--
PRIORITY APPLN. INFO.:      SE 1994-2170      19940620
                                SE 1994-2838      19940825
                                WO 1995-SE721      19950614
OTHER SOURCE(S):      MARPAT 124:261755
GI

```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title peptides [I; R1 = H, Me(CH₂)_n, PhCH₂CH₂, cyclopropylmethyl, CH₂:CHCH₂, H-Arg; wherein n = 0-12; R2 = H, Me (CH₂)_n, cyclopropylmethyl, CH₂:CHCH₂; wherein n = 0-12; R3 - R6 = H; R4 = R5 = H and R3 = R6 = C1-6 alkyl; R3 = R5 = R6 = H and R4 = F, Cl, Br, OH, NH₂, or NO₂; R7 = CO, CH₂; R8 = H, C1-6 alkyl; R9 = bivalent radical selected from Me(CH₂)_mCH, Me₂CHCH, Me₂CHCH₂CH, EtCHMeCH, HOCH₂CH, MeSCH₂CH₂CH, Q; wherein p = 0-4; R10 = OH, NH₂, Q1, Q2; R11 = H, NO₂, F, Cl, Br, iodo; q = 0-3; R12 = CO₂H, CONH₂, CH₂OH, any addnl. amino acid or peptide segment], which are useful in therapy, especially as analgesics and as immunosuppressive agents, are prepared Thus, 3.48 g BOP was added to a stirred solution of 2.8 g Boc-Tic-OH (N-tert-butoxycarbonyl-L-1,2,3,4-tetrahydroquinoline) and 1.33 mL Et₃N in CH₂Cl₂. After 5 min, 1.2 g N-dimethylhydroxylamine hydrochloride and 1.68 mL Et₃N were added and the reaction was carried out for 17 h to give, after silica gel chromatog., 65% N-tert-butoxycarbonyl-L-1,2,3,4-tetrahydroquinoline-3-N-methoxy-N-methylcarboxamide, which (1.2 g) was reduced by 190 mg LiAlH₄ in Et₂O for 1 h to give the aldehyde N-tert-butoxycarbonyl-L-1,2,3,4-tetrahydroquinoline-3-carboxaldehyde (Boc-Tic-H). The resin H-Cha-Phe-O-resin (Cha = cyclohexylalanine) (preparation given) was washed twice with DMF, successively treated with Boc-Tic-H in DMF containing 1% AcOH and then portion wise with 115 mg NaBH₃CN. After coupling the N-terminal tyrosine and deprotection, the peptide was cleaved from the resin, purified, and lyophilized to give H-Tyr-Tic[CH₂-NH]Cha-Phe-OH.

IT **174860-13-OP 174860-14-1P 174860-15-2P 174860-17-4P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of opioid peptide analogs as δ opioid receptor antagonists, analgesics, and immunosuppressants)

L15 ANSWER 29 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1996:17570 HCAPLUS

DOCUMENT NUMBER: 124:164281
 TITLE: Four different types of opioid peptides with mixed μ agonist/ δ antagonist properties
 AUTHOR(S): Schiller, P. W.; Weltrowska, G.; Schmidt, R.; Nguyen, T. M. -D.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes, B. C.
 CORPORATE SOURCE: Laboratory Chemical Biology and Peptide Research, Clinical Research Institute Montreal, Montreal, QC, H2W 1R7, Can.
 SOURCE: Analgesia (Elmsford, New York) (1995), 1(4-6), 703-6
 CODEN: AALGEB; ISSN: 1071-569X
 PUBLISHER: Cognizant Communication Corp.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Mixed μ agonist/ δ antagonists are thought to have potential as analgesics with low propensity to produce tolerance and dependence. The first balanced μ agonist/ δ antagonist was the pseudotetrapeptide H-Dmt-Tic ψ [CH₂-NH]Phe-Phe-NH₂ (DIPP-NH₂[ψ]; Dmt = 2',6'-dimethyltyrosine; Tic = tetrahydroisoquinoline-3-carboxylic acid), which showed very high μ agonist potency in the GPI assay, excellent δ antagonist potency in the MVD assay and μ and δ receptor affinities in the subnanomolar range. The dipeptide derivative H-Dmt-Tic-NH-(CH₂)₃-Ph (Ph = phenyl) displayed similarly high μ and δ receptor affinities and appears to be a mixed partial μ agonist/ δ antagonist. Another class of mixed μ agonist/ δ antagonists are cyclic β -casomorphin analogs containing a 2-naphthylalanine (2-Nal) residue in the 3-position of the peptide sequence, the prototype being H-Tyr-c[-D-Orn-2-Nal-D-Pro-Gly-]. An analog of this type, H-Dmt-c[-D-Orn-2-Nal-D-Pro-Gly-], also showed balanced μ agonist/ δ antagonist potencies in the subnanomolar range. The novel cyclic opioid peptide H-c(Lys-Dmt-D-Ala-Phe-Asp)-H₂ turned out to be yet another prototype of a mixed μ agonist/ δ antagonist.

IT 160429-68-5 173927-99-6

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (mixed μ agonist/ δ antagonist opioids as analgesics with low tolerance and dependence)

L15 ANSWER 30 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:7265 HCAPLUS
 DOCUMENT NUMBER: 124:75581
 TITLE: Conformational analysis of potent and very selective δ opioid dipeptide antagonists
 AUTHOR(S): Amodeo, P.; Balboni, G.; Crescenzi, O.; Guerrini, R.; Picone, D.; Salvadori, S.; Tancredi, T.; Temussi, P. A.
 CORPORATE SOURCE: ICMIB del CNR, via Toiano 6, 80072 Arco Felice, Naples, Italy
 SOURCE: FEBS Letters (1995), 377(3), 363-7
 CODEN: FEBLAL; ISSN: 0014-5793
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The δ selectivity and antagonism of peptides containing L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in second position can be attributed mainly to the Tyr-Tic unit. These properties can be further enhanced by substituting Tyr¹ with 2,6-dimethyl-L-tyrosyl (Dmt). Dmt-Tic-NH₂, Dmt-Tic-OH, Dmt-Tic-Ala-NH₂ and Dmt-Tic-Ala-OH are all more active and/ or selective than the corresponding [Tyr¹]-parent peptides. In fact, the selectivities of Dmt-Tic-OH and Dmt-Tic-Ala-OH are the highest ever recorded for opioid mols. The ¹H NMR spectra in a

DMSO/water mixture at 278 K reveal the presence of two similar conformers, characterized by a cis or trans Dmt-Tic bond, in all four peptides. A detailed conformational anal. in solution of Dmt-Tic-NH₂ shows that these conformers have a shape very similar to that of the bioactive conformation of Tyr-Tic-NH₂ and to that of naltrindole.

IT 172262-39-4 172262-40-7 172262-47-4

172262-48-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(conformational anal. of potent and selective δ -opioid dipeptide antagonists)

L15 ANSWER 31 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:944609 HCAPLUS

DOCUMENT NUMBER: 124:75511

TITLE: δ Opioidmimetic antagonists: prototypes for designing a new generation of ultrasensitive opioid peptides

AUTHOR(S): Salvadori, Severo; Attila, Martti; Balboni, Giofranco; Bianchi, Clementina; Bryant, Sharon D.; Crescenzi, Orlando; Guerrini, Remo; Picone, Delia; Tancredi, Teodorico; et al.

CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy

SOURCE: Molecular Medicine (Cambridge, Massachusetts) (1995), 1(6), 678-89

CODEN: MOMEF3; ISSN: 1076-1551

PUBLISHER: Blackwell

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Tyr-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) and Tyr-Tic-Ala were the first peptides with δ opioid antagonist activity lacking Phe, considered essential for opioid activity based on the N-terminal tripeptide sequence (Tyr-D-Xaa-Phe) of amphibian skin opioids. Analogs were then designed to restrain the rotational flexibility of Tyr by the substitution of 2,6-dimethyl-L-tyrosine (Dmt). Tyr and Dmt peptides were synthesized by solid phase and solution methods using Fmoc technol. or condensing Boc-Dmt-OH or Boc-Tyr(But)-OH with H-L-Tic-OBu or H-D-Tic-OBu, resp. Peptides were purified (>99%) by HPLC and characteristics determined by 1H-NMR, FAB-MS, m.p., TLC, and amino acid analyses. H-Dmt-Tic-OH had high affinity ($K_{i\delta} = 0.022$ nM) and extraordinary selectivity ($K_{i\mu}/K_{i\delta} = 150,000$); H-Dmt-Tic-Ala-OH had a $K_{i\delta} = 0.29$ nM and δ selectivity = 20,000. Affinity and selectivity increased 8700- and 1000-fold relative to H-Tyr-Tic-OH, resp. H-Dmt-Tic-OH and H-Dmt-Tic-NH₂ fitted one-site receptor binding models ($\eta = 0.939-0.987$), while H-Dmt-Tic-ol, H-Dmt-Tic-Ala-OH and H-Dmt-Tic-Ala-NH₂ best fitted two-site models ($\eta = 0.708-0.801$, F 18.9-26.0, $p < 0.0001$). Amidation increased μ affinity by 10- to 100-fold and acted synergistically with D-Tic₂ to reverse selectivity ($\delta \rightarrow \mu$). Dmt-Tic di- and tripeptides exhibited δ antagonist bioactivity ($K_e = 4-66$ nM) with mouse vas deferens and lacked agonist μ activity (> 10 μ M) in guinea-pig ileum preps. Dmt-Tic analogs weakly interacted with κ receptors in the 1 to >20 μ M range. Dmt-Tic opioidmimetic peptides represent a highly potent class of opioid peptide antagonists with greater potency than the nonopioid δ antagonist naltrindole and have potential application as clin. and therapeutic compds.

IT 172262-39-4P 172262-40-7P 172262-41-8P

172262-42-9P 172262-43-0P 172262-47-4P

172262-48-5P 172339-67-2P 172339-68-3P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); PROC (Process); USES (Uses)
 (δ opioidmimetic antagonists: prototypes for designing a new
 generation of ultrasensitive opioid peptides)

L15 ANSWER 32 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:428717 HCAPLUS
 DOCUMENT NUMBER: 122:188168
 TITLE: Preparation of peptides as δ opioid antagonists.
 INVENTOR(S): Schiller, Peter
 PATENT ASSIGNEE(S): Aktiebolaget Astra, Swed.
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9415959	A1	19940721	WO 1993-SE1090	19931220 <--
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2152380	AA	19940721	CA 1993-2152380	19931220 <--
AU 9458448	A1	19940815	AU 1994-58448	19931220 <--
AU 681372	B2	19970828		
EP 678099	A1	19951025	EP 1994-904365	19931220 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 72597	A2	19960528	HU 1995-2041	19931220 <--
JP 08505386	T2	19960611	JP 1993-515914	19931220 <--
US 5602099	A	19970211	US 1994-176938	19940104 <--
ZA 9400055	A	19940705	ZA 1994-55	19940105 <--
CN 1096515	A	19941221	CN 1994-100129	19940105 <--
LV 10962	B	19970420	LV 1995-197	19950629 <--
FI 9503302	A	19950704	FI 1995-3302	19950704 <--
NO 9502650	A	19950830	NO 1995-2650	19950704 <--

PRIORITY APPLN. INFO.: SE 1993-12 19930105
 WO 1993-SE1090 19931220

OTHER SOURCE(S): MARPAT 122:188168
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = H, Me(CH₂)_n, PhCH₂CH₂, cyclopropylmethyl, allyl, H-Arg; R2 = H, Me(CH₂)_n, cyclopropylmethyl, allyl, etc.; n = 0-12; R3-R6 = H, or R4, R5 both = H and R3, R6 both = lower alkyl, or R3, R5, R6all = H and R4 = F, Cl, Br, OH, NH₂, NO₂; R7 = CO, CH₂; R8 = H, lower alkyl; R9 = Q1-Q7; m = 0-2; R10 = H, F, Cl, Br, iodo; R11 = OH, NH₂, Q8, Q9; R12 = H, NO₂, F, Cl, Br, iodo; m = 0-2; R13, R14 = CO₂H, CONH₂, CH₂OH, amino acid or peptide segment; with the exceptions of compds. where R1, R2, R3, R4, R5, R6, R8 all = H, R7 = CO, R9 = PhCH₂CH₂, and R11 = Phe-OH, Phe-NH₂, OH, NH₂], were prepared Thus, H-Tyr-Tic-Hfe-Phe-OH (Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylate; Hfe = homophenylalanyl), was prepared by solid phase synthesis. I antagonized [Leu⁵] enkephalin in mouse vas deferens with Ke = 0.169-43.9 nM.

IT 156219-37-3 160429-67-4 160429-68-5
 161669-02-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptides as δ opioid antagonists)

L15 ANSWER 33 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:259490 HCAPLUS

DOCUMENT NUMBER: 122:71781

TITLE: A highly potent TIPP-NH₂ analog with balanced mixed μ agonist/ δ antagonist properties

AUTHOR(S): Schiller, P. W.; Weltrowska, G.; Nguyen, T. M.-D.; Lemieux, C.; Chung, N. N.; Wilkes, B. C.

CORPORATE SOURCE: Lab. Chem. Biol. Peptide Res., Clin. Res. Inst. Montreal, Montreal, QC, H2W 1R7, Can.

SOURCE: Regulatory Peptides (1994), 54(1), 257-8
CODEN: REPPDY; ISSN: 0167-0115

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The tetrapeptide amide H-Tyr-Tic-Phe-Phe-NH₂ (TIPP-NH₂; Tic = tetrahydroisoquinoline-3-carboxylic acid) has recently been shown to be a moderately potent μ opioid agonist and a highly potent δ opioid antagonist, thus representing the first known example of a mixed μ agonist/ δ antagonist. In an effort to strengthen the μ agonist component of TIPP-NH₂, the authors substituted 2',6'-dimethyltyrosine (Dmt) for Tyr¹. The analogs H-Dmt-Tic-Phe-Phe-NH₂ (DIPP-NH₂) and H-Dmt-Tic Ψ [CH₂-NH]Phe-Phe-NH₂ (DIPP-NH₂ Ψ) were both potent μ agonists in the GPI assay (IC₅₀ = 13.5 nM and 7.71 nM, resp.) and potent antagonists against δ agonists in the MVD assay (K_e approx. 0.2 nM and 0.5 nM, resp.). In the rat brain membrane binding assays, DIPP-NH₂ and DIPP-NH₂ Ψ showed very high μ receptor affinities (K_{i μ} = 1.19 nM and 0.94 nM, resp.) and δ receptor affinities (K_{i δ} = 0.12 nM and 0.45 nM, resp.). DIPP-NH₂ Ψ represents the first known opioid compound with balanced mixed μ agonist/ δ antagonist properties.

IT 160429-67-4 160429-68-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(highly potent tetrapeptide amide analog with balanced mixed μ opioid agonist/ δ opioid antagonist properties)

L15 ANSWER 34 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:450365 HCAPLUS

DOCUMENT NUMBER: 121:50365

TITLE: TIPP analogs: highly selective δ opioid antagonists with subnanomolar potency and first known compounds with mixed μ agonists/ δ antagonist properties

AUTHOR(S): Schiller, P. W.; Weltrowska, G.; Nguyen, T. M. D.; Chung, N.; Lemieux, C.; Wilkes, B. C.

CORPORATE SOURCE: Lab. Chem. Biol. Peptides Res., Clin. Res. Inst. Montreal, Montreal, QC, H2W 1R7, Can.

SOURCE: Regulatory Peptides (1994), (Suppl. 1), S63-S64
CODEN: REPPDY; ISSN: 0167-0115

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Analogs of the potent and highly selective δ -opioid antagonist H-Tyr-Tic-Phe-Phe-OH (TIPP) (Tic = tetrahydroisoquinoline-3-carboxylic acid) containing Trp, 3-(2'-naphthyl)alanine (2-Nal), or homophenylalanine (Hfe) in place of Phe³, or p-nitrophenylalanine [Phe(pNO₂)] in place of Phe⁴ exhibited a 1.5-5-fold increase in δ antagonist potency against δ agonists in the mouse vas deferens (MVD) assay and 3-5-fold enhanced δ selectivity. The pseudopeptide H-Tyr-Tic Ψ [CH₂-NH]Phe-

Phe-OH (TIPP[Ψ]) showed excellent stability against enzymic degradation, high δ antagonist potency (K_e .apprx.2.5 nM), no μ antagonist properties, and unprecedented δ selectivity, being 500 times more selective than the nonpeptide δ antagonist naltrindole. The analog H-Dmt-Tic-Phe-Phe-OH (DIPP) (Dmt = 2,6-dimethyltyrosine) displayed a K_e of 0.15 nM and is the most potent δ antagonist reported to date. Both H-Tyr-Tic-Phe-Phe-NH₂ and DIPP were moderately potent, full μ agonists in the guinea pig ileum assay and thus represent the first mixed μ agonist/ δ antagonists known.

IT 156219-37-3

RL: BIOL (Biological study)
(as μ agonist/ δ antagonist)

=> select hit rn l15 1-34
E1 THROUGH E164 ASSIGNED

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:45:41 ON 18 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUN 2004 HIGHEST RN 694921-36-3
DICTIONARY FILE UPDATES: 17 JUN 2004 HIGHEST RN 694921-36-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
=>

=> =>
=> d his l16

(FILE 'HCAPLUS' ENTERED AT 16:44:34 ON 18 JUN 2004)
SELECT HIT RN L15 1-34

L16 FILE 'REGISTRY' ENTERED AT 16:45:41 ON 18 JUN 2004
164 S E1-E164

=>
=> d reg l16 1-164

1	RN	344615-79-8	REGISTRY
2	RN	344615-78-7	REGISTRY
3	RN	344615-77-6	REGISTRY
4	RN	344615-76-5	REGISTRY
5	RN	329320-07-2	REGISTRY
6	RN	329320-06-1	REGISTRY
7	RN	329320-05-0	REGISTRY
8	RN	329320-04-9	REGISTRY

9	RN	329320-03-8	REGISTRY
10	RN	329320-02-7	REGISTRY
11	RN	329320-01-6	REGISTRY
12	RN	329320-00-5	REGISTRY
13	RN	329319-99-5	REGISTRY
14	RN	329319-98-4	REGISTRY
15	RN	329319-97-3	REGISTRY
16	RN	329319-96-2	REGISTRY
17	RN	262616-51-3	REGISTRY
18	RN	262616-50-2	REGISTRY
19	RN	262616-49-9	REGISTRY
20	RN	262616-48-8	REGISTRY
21	RN	262616-47-7	REGISTRY
22	RN	262616-46-6	REGISTRY
23	RN	262616-45-5	REGISTRY
24	RN	262616-44-4	REGISTRY
25	RN	262616-43-3	REGISTRY
26	RN	262616-42-2	REGISTRY
27	RN	262616-41-1	REGISTRY
28	RN	262616-40-0	REGISTRY
29	RN	262616-39-7	REGISTRY
30	RN	262616-38-6	REGISTRY
31	RN	262616-37-5	REGISTRY
32	RN	262616-36-4	REGISTRY
33	RN	262616-35-3	REGISTRY
34	RN	262616-34-2	REGISTRY
35	RN	254102-28-8	REGISTRY
36	RN	254102-27-7	REGISTRY
37	RN	254102-26-6	REGISTRY
38	RN	254102-25-5	REGISTRY
39	RN	254102-21-1	REGISTRY
40	RN	254102-17-5	REGISTRY
41	RN	254102-13-1	REGISTRY
42	RN	254102-12-0	REGISTRY
43	RN	254102-11-9	REGISTRY
44	RN	254102-09-5	REGISTRY
45	RN	254102-07-3	REGISTRY
46	RN	254102-06-2	REGISTRY
47	RN	254102-03-9	REGISTRY
48	RN	254102-02-8	REGISTRY
49	RN	254102-01-7	REGISTRY
50	RN	254102-00-6	REGISTRY
51	RN	254101-98-9	REGISTRY
52	RN	254101-96-7	REGISTRY
53	RN	254101-94-5	REGISTRY
54	RN	254101-92-3	REGISTRY
55	RN	254101-90-1	REGISTRY
56	RN	254101-88-7	REGISTRY
57	RN	254101-86-5	REGISTRY
58	RN	254101-84-3	REGISTRY
59	RN	254101-82-1	REGISTRY
60	RN	254101-80-9	REGISTRY
61	RN	254101-78-5	REGISTRY
62	RN	254101-77-4	REGISTRY
63	RN	254101-75-2	REGISTRY
64	RN	254101-66-1	REGISTRY
65	RN	250331-76-1	REGISTRY
66	RN	245538-29-8	REGISTRY
67	RN	245538-28-7	REGISTRY
68	RN	220045-96-5	REGISTRY
69	RN	220045-95-4	REGISTRY
70	RN	220045-94-3	REGISTRY
71	RN	220045-93-2	REGISTRY


72	RN	220045-92-1	REGISTRY
73	RN	220045-90-9	REGISTRY
74	RN	215597-37-8	REGISTRY
75	RN	215597-26-5	REGISTRY
76	RN	215596-98-8	REGISTRY
77	RN	209786-80-1	REGISTRY
78	RN	209786-79-8	REGISTRY
79	RN	209786-77-6	REGISTRY
80	RN	209786-71-0	REGISTRY
81	RN	204764-01-2	REGISTRY
82	RN	202860-57-9	REGISTRY
83	RN	202860-56-8	REGISTRY
84	RN	202860-55-7	REGISTRY
85	RN	202860-54-6	REGISTRY
86	RN	202860-53-5	REGISTRY
87	RN	195832-13-4	REGISTRY
88	RN	195831-88-0	REGISTRY
89	RN	195831-86-8	REGISTRY
90	RN	195831-84-6	REGISTRY
91	RN	195831-82-4	REGISTRY
92	RN	195831-80-2	REGISTRY
93	RN	195831-78-8	REGISTRY
94	RN	195831-77-7	REGISTRY
95	RN	195831-75-5	REGISTRY
96	RN	195831-73-3	REGISTRY
97	RN	195831-71-1	REGISTRY
98	RN	195831-69-7	REGISTRY
99	RN	195831-67-5	REGISTRY
100	RN	195831-65-3	REGISTRY
101	RN	195831-63-1	REGISTRY
102	RN	195831-61-9	REGISTRY
103	RN	195831-59-5	REGISTRY
104	RN	195831-57-3	REGISTRY
105	RN	195831-55-1	REGISTRY
106	RN	195831-53-9	REGISTRY
107	RN	194857-81-3	REGISTRY
108	RN	194857-80-2	REGISTRY
109	RN	194857-79-9	REGISTRY
110	RN	194857-76-6	REGISTRY
111	RN	194857-74-4	REGISTRY
112	RN	194857-73-3	REGISTRY
113	RN	194857-72-2	REGISTRY
114	RN	194857-71-1	REGISTRY
115	RN	194857-70-0	REGISTRY
116	RN	194857-69-7	REGISTRY
117	RN	194857-66-4	REGISTRY
118	RN	194857-64-2	REGISTRY
119	RN	194857-63-1	REGISTRY
120	RN	194857-62-0	REGISTRY
121	RN	194857-61-9	REGISTRY
122	RN	194857-60-8	REGISTRY
123	RN	194857-55-1	REGISTRY
124	RN	194857-52-8	REGISTRY
125	RN	193897-93-7	REGISTRY
126	RN	189094-51-7	REGISTRY
127	RN	189094-07-3	REGISTRY
128	RN	189094-05-1	REGISTRY
129	RN	189094-01-7	REGISTRY
130	RN	189093-95-6	REGISTRY
131	RN	189093-93-4	REGISTRY
132	RN	179091-75-9	REGISTRY
133	RN	179091-74-8	REGISTRY
134	RN	178951-52-5	REGISTRY

135	RN	178951-51-4	REGISTRY
136	RN	178951-50-3	REGISTRY
137	RN	178951-49-0	REGISTRY
138	RN	178951-48-9	REGISTRY
139	RN	178951-47-8	REGISTRY
140	RN	178951-46-7	REGISTRY
141	RN	178951-45-6	REGISTRY
142	RN	178951-42-3	REGISTRY
143	RN	178752-57-3	REGISTRY
144	RN	178752-53-9	REGISTRY
145	RN	178752-50-6	REGISTRY
146	RN	178752-43-7	REGISTRY
147	RN	174860-17-4	REGISTRY
148	RN	174860-15-2	REGISTRY
149	RN	174860-14-1	REGISTRY
150	RN	174860-13-0	REGISTRY
151	RN	173927-99-6	REGISTRY
152	RN	172339-68-3	REGISTRY
153	RN	172339-67-2	REGISTRY
154	RN	172262-48-5	REGISTRY
155	RN	172262-47-4	REGISTRY
156	RN	172262-43-0	REGISTRY
157	RN	172262-42-9	REGISTRY
158	RN	172262-41-8	REGISTRY
159	RN	172262-40-7	REGISTRY
160	RN	172262-39-4	REGISTRY
161	RN	161669-02-9	REGISTRY
162	RN	160429-68-5	REGISTRY
163	RN	160429-67-4	REGISTRY
164	RN	156219-37-3	REGISTRY

=> d ide can 116 1 5 13 17 35 51 65 66 68 74 76 77 81

L16 ANSWER 1 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
RN 344615-79-8 REGISTRY
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[(2R)-3-(4-hydroxy-2,6-dimethylphenyl)-2-(methylamino)-1-oxopropyl]-N-(2-phenylethyl)-, (3S)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H35 N3 O3
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Conference
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:40848

L16 ANSWER 5 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
RN **329320-07-2** REGISTRY
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-6-fluoro-1,2,3,4-tetrahydro-, (3S)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C21 H23 F N2 O4
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:216792

L16 ANSWER 13 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **329319-99-5** REGISTRY
 CN 7-Isoquinolinamine, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H25 N3 O2
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Cplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:216792

L16 ANSWER 17 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **262616-51-3** REGISTRY
 CN 3-Isoquinolinecarboxylic acid, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-7-methoxy-6-(4-methoxyphenyl)-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H32 N2 O6
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Cplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:245845

L16 ANSWER 35 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN **254102-28-8** REGISTRY

CN Carbamic acid, [(1S)-2-[(3S)-3-[[[(1S)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-1-[(4-hydroxy-2,6-dimethylphenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C33 H46 N4 O6

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

REFERENCE 2: 132:73213

L16 ANSWER 51 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN 254101-98-9 REGISTRY

CN L-Alanine, N-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinoliny]carbonyl]-, methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C25 H31 N3 O5 . C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

CM 1

CRN 254101-97-8

CMF C25 H31 N3 O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

REFERENCE 2: 132:73213

L16 ANSWER 65 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **250331-76-1** REGISTRY
 CN 3-Isoquinolinecarboxylic acid, 2-[(2S,3R)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxobutyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN TMT-Tic

FS STEREOSEARCH

MF C22 H26 N2 O4

CI COM

SR CA


LC STN Files: BIOSIS, CA, CAPLUS

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study)

RL.NP Roles from non-patents: BIOL (Biological study)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:143750

REFERENCE 2: 139:111815


REFERENCE 3: 138:248480

REFERENCE 4: 131:347049

L16 ANSWER 66 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **245538-29-8** REGISTRY
 CN L-Phenylalaninamide, N-[[[(3S)-1,2,3,4-tetrahydro-2-[(2S)-3-(4-hydroxy-2,6-dimethylphenyl)-2-(methylamino)-1-oxopropyl]-3-isoquinolinyl]methyl]-L-phenylalanyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C40 H47 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:266894

L16 ANSWER 68 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN **220045-96-5** REGISTRY

CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-(dimethylamino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C23 H26 N2 O4 T2


SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Conference; Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties)

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 133:99680

REFERENCE 2: 131:214535

REFERENCE 3: 130:139633

L16 ANSWER 74 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **215597-37-8** REGISTRY
 CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-[3-(1H-indol-3-yl)-1-oxopropyl]-, (3S)-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H33 N3 O3
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Conference
 RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:339945

L16 ANSWER 76 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **215596-98-8** REGISTRY
 CN Isoquinoline, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-(1-oxo-3-phenylpropyl)-, (3S)-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H32 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Conference
 RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:339945

L16 ANSWER 77 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
RN **209786-80-1** REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[(2R)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-(2,2-diphenylethyl)-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H37 N3 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 129:95725

L16 ANSWER 81 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
RN **204764-01-2** REGISTRY
CN 1-11-Dynorphin A (swine), 1-(N,O-dimethyl-L-tyrosine)-2-[(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid]-11-L-lysineamide- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C73 H114 N22 O12
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:226374

=>

=>

=> d ide can 116 82 87 88 107 125 126 130 132 134 143 147 151 152 154 161 162 164


L16 ANSWER 82 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN 202860-57-9 REGISTRY

CN 3-Isoquinolinecarboxylic acid, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxobutyl]-1,2,3,4-tetrahydro-, phenylmethyl ester, monohydrochloride, [3S-[2(2S*,3S*),3R*]]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
 MF C29 H32 N2 O4 . Cl H
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 PROC (Process); PRP (Properties)

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:162532

L16 ANSWER 87 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **195832-13-4** REGISTRY
 CN Carbamic acid, [2-[3,4-dihydro-3-[[2-hydroxy-3-phenylpropyl)amino]carbonyl]-2(1H)-isoquinolinyl]-1-[(4-hydroxy-2,6-dimethylphenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, [3S-[3R*(S*)]]-[partial]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C35 H43 N3 O6
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:248425

L16 ANSWER 88 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
RN **195831-88-0** REGISTRY
CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-N-[2-(4-fluorophenyl)ethyl]-1,2,3,4-tetrahydro-, [S-(R*,S*)]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H32 F N3 O3 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Cplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CM 1
CRN 195831-87-9
CMF C29 H32 F N3 O3

Absolute stereochemistry.

CRN 76-05-1
CMF C2 H F3 O2




REFERENCE 1: 127:248425

```
L16 ANSWER 107 OF 164  REGISTRY  COPYRIGHT 2004 ACS on STN
RN  194857-81-3  REGISTRY
CN  3-Isoquinolinecarboxylic acid, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-
    1-oxopropyl]-1,2,3,4-tetrahydro-, (3S)-, mono(trifluoroacetate) (salt)
    (9CI)  (CA INDEX NAME)
FS  STEREOSEARCH
MF  C21 H24 N2 O4 . C2 H F3 O2
SR  CA
LC  STN Files:  CA, CAPLUS
DT.CA  CAplus document type:  Journal
RL.NP  Roles from non-patents:  PREP (Preparation); RACT (Reactant or reagent)
```

CRN 194857-80-2
CMF C21 H24 N2 O4


Page 80



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:214595

L16 ANSWER 125 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN **193897-93-7** REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-, [S-(R*,R*)]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C21 H25 N3 O3 . C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Journal


RL.NP Roles from non-patents: RACT (Reactant or reagent)

CM 1

CRN 172262-40-7

CMF C21 H25 N3 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:171672

L16 ANSWER 126 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN 189094-51-7 REGISTRY

CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-[3-(4-hydroxy-2,6-dimethylphenyl)-2-(methylamino)-1-oxopropyl]-, [S-(R*,R*)]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C22 H26 N2 O4 . C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Journal


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

CM 1

CRN 178951-51-4

CMF C22 H26 N2 O4


Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:214595

REFERENCE 2: 126:288045

L16 ANSWER 130 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN 189093-95-6 REGISTRY

CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-, (3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C21 H24 N2 O4 . C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: RACT (Reactant or reagent)


RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

CM 1

CRN 172262-39-4

CMF C21 H24 N2 O4


Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



4 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140

REFERENCE 2: 132:73213

REFERENCE 3: 127:214595

REFERENCE 4: 126:288045

L16 ANSWER 132 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN **179091-75-9** REGISTRY

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-hydroxy-2,6-dimethylphenyl)-2-(methylamino)-1-oxopropyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C22 H27 N3 O3

CI COM


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 125:105145

L16 ANSWER 134 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
RN **178951-52-5** REGISTRY
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[(2S)-3-(4-hydroxy-2,6-dimethylphenyl)-2-(methylamino)-1-oxopropyl]-, (3S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-hydroxy-2,6-dimethylphenyl)-2-(methylamino)-1-oxopropyl]-, [S-(R*,R*)]-

FS STEREOSEARCH

MF C22 H27 N3 O3

CI COM

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Conference; Patent

RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study)

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:200061

REFERENCE 2: 125:105145

L16 ANSWER 143 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **178752-57-3** REGISTRY
 CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C31 H34 N4 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 125:87219


L16 ANSWER 147 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **174860-17-4** REGISTRY
 CN L-Phenylalanine, N-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]-3-cyclohexyl-L-alanyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C39 H50 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 124:261755

L16 ANSWER 151 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN 173927-99-6 REGISTRY

CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-(3-phenylpropyl)-, (3S)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3-Isoquinolinecarboxamide, 2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-(3-phenylpropyl)-, [S-(R*,R*)]-

FS STEREOSEARCH

MF C30 H35 N3 O3

CI COM


SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Conference; Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:40848

REFERENCE 2: 129:245476

REFERENCE 3: 124:164281

L16 ANSWER 152 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN **172339-68-3** REGISTRY

CN L-Alaninamide, 2,6-dimethyl-L-tyrosyl-D-1,2,3,4-tetrahydro-3-isoquinolinecarboxyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C24 H30 N4 O4

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 125:105145

REFERENCE 2: 124:75511

L16 ANSWER 154 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN 172262-48-5 REGISTRY

CN L-Alaninamide, 2,6-dimethyl-L-tyrosyl-(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarboxyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Alaninamide, 2,6-dimethyl-L-tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarboxyl-

OTHER NAMES:

CN DTA (peptide)

FS STEREOSEARCH

MF C24 H30 N4 O4

CI COM

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:338140
REFERENCE 2: 135:235885
REFERENCE 3: 134:66089
REFERENCE 4: 132:73213
REFERENCE 5: 125:105145
REFERENCE 6: 124:75581
REFERENCE 7: 124:75511

L16 ANSWER 161 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN **161669-02-9** REGISTRY

CN L-Phenylalanine, N-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]-L-phenylalanyl]-
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Phenylalanine, N-[N-[[[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]-L-phenylalanyl]-, [S-(R*,R*)]-

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C39 H44 N4 O5

SR CA

LC STN Files: CA, CAPLUS, USPATFULL


DT.CA Caplus document type: Conference; Patent

RL.P Roles from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:26958

REFERENCE 2: 122:188168

L16 ANSWER 162 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN

RN **160429-68-5** REGISTRY

CN L-Phenylalaninamide, N-[[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl)methyl]-L-phenylalanyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Phenylalaninamide, N-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinyl)methyl]-L-phenylalanyl-, [S-(R*,R*)]-

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C39 H45 N5 O4

SR CA

LC STN Files: CA, CAPLUS, USPATFULL


DT.CA Caplus document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.




6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:266894
REFERENCE 2: 129:245476
REFERENCE 3: 126:1296
REFERENCE 4: 124:164281
REFERENCE 5: 122:188168
REFERENCE 6: 122:71781

L16 ANSWER 164 OF 164 REGISTRY COPYRIGHT 2004 ACS on STN
RN **156219-37-3** REGISTRY
CN L-Phenylalanine, 2,6-dimethyl-L-tyrosyl-(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarboxyl-L-phenylalanyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Phenylalanine, 2,6-dimethyl-L-tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarboxyl-L-phenylalanyl-
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C39 H42 N4 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:12871
REFERENCE 2: 129:245476
REFERENCE 3: 122:188168
REFERENCE 4: 121:50365

=>